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Abstract 
This quantitative systematic review has focussed on eight studies for a meta-
analysis that has provided significant and positive evidence for the atypical 
antipsychotic, aripiprazole, on weight loss. Aripiprazole has been compared to 
other antipsychotics such as olanzapine, quetiapine, risperidone and 
haloperidol on weight loss (N= 2, 507). Although it has been argued that there 
is weight loss due to aripiprazole (Beebe, 2003), discussion of this treatment 
for mental illness has to be understood with respect to the psychological as 
well as the physical and adverse effects of taking antipsychotic medication. 
The significant factor that has emerged for a longer lasting solution for 
maintaining weight loss in the treatment of mental illness and psychoses is the 
integrative approach which has a psychological design (Citrome & Yeo+mans, 
2005). This is most supportive for the sufferer, where clinicians respond to 
their issue armed with the knowledge from research and evidence-based 
practices for a long term treatment of weight management (Lean, 2003). The 
meta-analyses results was highly significant at - 6.700 at p< or equal to 
0.0001 that indicated that the hypothesis was supported with weight loss for 
aripiprazole compared to other antipsychotics in this review. 
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1.lntroduction 
This systematic review investigates if weight loss occurs by taking the atypical 
antipsychotic aripiprazole, for people who have been diagnosed with 
schizophrenia or bipolar I disorder. The rationale is based on research that 
has shown a positive new trend amongst the second and third generation of 
atypical antipsychotics that are counteracting some of the side effects better 
(Ehret et al., 2008). Since the introduction of the first generation of 
conventional antipsychotics from the 1950s of chlorpromazine and haloperidol 
(Comer, 2007, p.442) to the 1980s (IVlcEnany, 2007) of second generation 
antipsychotics (SGAs) the significance of weight gain became important 
because there was weight gain with this latter group (Beebe, 2003). It is 
necessary to review this issue of weight management as advances in science 
support the psychological and emotional impact on self esteem and self 
management for not just the healthy population, but the mentally ill (Paton et 
al., 2004). If aripiprazole is an effective atypical antipsychotic agent with an 
impact on weight loss compared to other antipsychotics and some atypical 
antipsychotics, then this is truly an advantage (Ehret et al., 2008) and crucial 
to public health (Faulkner et al., 2003). 
1. 1 Atypical versus typical antipsychotic 
The effects of antipsychotics have been seen frequently in the treatment of 
psychoses such as schizophrenia for which antipsychotics was pioneering 
work (Marder et al, 2003), as well as for depression, delusional disorders and 
dementia (Gardner et al., 2005, p.1703). Schizophrenia has been known to be 
best treated with antipsychotic medication and particularly when it is a long 
term illness (Naber & Lambert, 2004). These older antipsychotic drugs were 
also known as 'neuroleptic drugs' since they could cause movement disorders 
that mimicry 'neurological disease' (Comer, 2007, p.442), and these side 
effects were not treated because the drugs were not as sophisticated as they 
are now to improve these conditions (Gardner et al., 2005). 
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The neurologic side effects are less in the atypical antipsychotics (Schultz et 
a/., 2007), which have adverse effects that are different from the first 
generation of antipsychotic medications (McEnany, 2007). These SGAs are 
different from the typical antipsychotics in their action because they do not 
create the movement disorders (known as the Extrapyrarnidal symptoms -
EPS) when treating the mental illness (Gardner et al., 2005). But the atypical 
antipsychotics have the disadvantage of causing metabolic disturbances and 
weight gain as will be discussed later (Ehret et al., 2008; Schultz et al., 2007). 
Though, there has been extensive research on the new antipsychotics with 
enhanced knowledge of the biochemical effects, the scientists still cannot 
eliminate treatment effects for all the symptoms of psychoses (Miyamoto et 
al., 2005). 
There has been 
Psychoses and mental illness 
a rise in the numbers of people suffering mental illness since 
with this are problems 
homelessness' 
the last decade (Fox, 1999). This is disconcerting as it implies that together 
the of 'suicide, drug and alcohol abuse and 
(ibid, p.41 2) Other problems associated for people with 
psychoses are generally a greater risk of serious illnesses such as diabetes 
and cardiovascular disease (CVD) related to inactivity and medication more 
so than the general population (Paton et al., 2004). Connolly and Kelly (2005 )  
address that there is inadequate physical health for those suffering mental 
health and more needs to be done in this area to develop better practices 
professionally to support them. 
Psychosis has been defined as a 'loss of contact with reality' and is frequently 
associated with the illness schizophrenia (Comer, 2007, p.411 ). This 
explanation may be because it has been thought of as an illness with a lack of 
insight into the nature of the condition which has 'hallucinations' or 'delusions' 
(American Psychiatric Association, APA, 1994, p.273). It has also been linked 
to using 'LSD or abusing amphetamines or cocaine' (Comer, 2007, p.41 1  ). 
Schizophrenia 
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The American Psychiatric Association (APA, 1994) has produced a diagnostic 
and statistical manual of mental disorders (DSM-IV) which Comer (2007) has 
recommended in the diagnosis of schizophrenia Clinicians recognise this 
disease when symptoms of this disorder manifests as deterioration in 'work, 
social relations', and personal care (Comer, 2007, p.423). There are 'positive' 
and 'negative symptoms' in schizophrenia as well as 'psychomotor' ones 
(Comer, 2007, p.416). The positive symptoms are described as 'excesses 
are 
or 
distortion of normal functions' whereas the negative symptoms of 
'diminution or loss of normal functions' (APA, 1994, p.274). The APA 
considers various researches and posits that there is a 'lifetime prevalence of 
schizophrenia between - 0.5% and 1 %' (p.282). 
In an explanation of the aetiology of the disease, the most popular theory is 
for the biological perspective, which is associated with genetic issues. This 
suggests that the onset of the disease is caused by stress in the early 
twenties 
Bipolar I disorder 
or late teens, and this varies for both men and women with there 
being no gender difference in the precipitation of the disease (Comer, 2007). 
DSM -IV-TR recognises two types of bipolar disorders - bipolar I and bipolar 
I I  disorder (Comer, 2007, p.243). Bipolar I disorder consists of 'full manic and 
major depressive episodes' with the 'full manic episode' lasting for a week or 
more of an unusually euphoric emotional state 'or irritable mood, along with at 
least three other symptoms of mania' (Comer, 2007, p.243). This stage could 
cause 'delusions or hallucinations' (ibid, p.243). There is an 'alternation' of the 
stages. The most recent theory explaining this disease has been one of the 
neurotransmitter activities with a 'low serotonin activity' together with 'high 
norepinephrine activity' that 'may lead to mania' (Comer, 2007, p.245). 
Genetics cannot be ruled out as a risk factor since family studies have 
provided evidence for development of the disorder as well (ibid). The 'lifetime 
prevalence .. in community samples ... 0.4% to 1.6%'' (APA, 1994, p.353). 
Aripiprazole 
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The finding is that aripiprazole is more effective in the treatment of 
schizophrenia (Bandelow & Meier, 2003) and it is much less problematic in 
not just weight ga in but diabetes (Ehret et al. , 2008)&. As it is a recent drug for 
Aripiprazole was brought in to treat schizophrenia in the 1 990s as an atypical 
agent and it is the most recent drug intervention (Beebe, 2003). Generally the 
atypical antipsychotics cause greater weight gain and cost more , but the 
action of aripiprazole has benefit because it has less weight gain (Beebe, 
2003). It has a trade name known as 'Abi!ify' (Comer, 2007, p.445) and is 
seen in this meta-analysis to be consistently used in the treatment of 
schizophrenia, although it is also seen to be treating bipolar I disorder (Vieta 
et al. ,  2005 ; Keck et al. , 2003). 
there are only short-term published studies available these treatments, 
(Beebe, 2003). Shajahan et al. (2008) consider aripiprazole to be of unique 
benefit compared to other atypicals i n  the treatment of psychoses. Whereas, 
El Sayeh and Morganti (2007) did not believe that aripiprazole is of real 
uniqueness from other antipsychotics (and atypicals) for schizophrenia 
because clinical studies have been no different substantially from other drugs. 
Aripiprazole was introduced as the new th i rd generation of atypical 
antipsychotics, and it is similar in composition to the typical antipsychotics of 
the first generation (Bhattacharjee George & EI-Sayeh, 2008) such as 
haloperidol. It is used in many countries including the U K  (Bandelow & Meier , 
2003). 
not gaining m uch weight have been equated with the antipsychotics 
amisulpride and ziprasidone where each causes less than 2 kilograms of 
weight gain (Newcomer, 2004, p . 1 936). By contrast olanzapine has been 
found to cause '4-1 0' kilogram of weight gain ( ibid, p. 1 936) It is important to 
note that the increase in weight ga in is varied amongst individuals (Connolly & 
Kelly, 2005) .  
1 . 2  Weight gain 
In fact weight gain is known to be considerable in some of the atypical 
antipsychotics (Zipursky et al. , 2005). The benefits of tak ing ar ipiprazole and 
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People with psychoses have increased risks for the secondary complications 
of being overweight or obesity, that are related to the factors that this group 
have sedentary lifestyles and possible depression and sluggishness due to 
their medication (Marder et al. ,  2003 ;  Paton et al., 2004). Together with 
smoking , a bad diet and little exercise the body's cardiovascular system is 
exacerbated for this group (Thomas, 2007 , p. S119; Marder et al. , 2003) more 
so than the general population (Paton et al. , 2004)&. 
It is necessary to consider the patients emotional feelings when there is 
weight gain because as secondary implications become a concern for people 
taking medication they may discontinue which could then be a contributory 
Carpenter et al. ,  2000; Connolly & Kelly , 2005 ;  Weil et al. , 2002) . The issues 
of weight gain and the metabolic side effects have become 
factor to relapse in mental illness (Naber & Lambert, 2004). The 
salient features of 
need to 
address the underlying emotional issues associated with weight gain is 
important, as seen in some studies in this review (De Souza & Ciclitira, 2005;  
Ascher-Svanum et al. ,  2005 ;  Addington et al. ,2003 ;  Wadden et al. 2004; 
importance when treatment with atypical antipsychotics are considered by 
clinicians and there is some choice for the patient that is in view of their 
concern for their image (Thomas, 2007) . 
The time span for incremental weight also differs considerably from patient to 
patient (lean ,  200 3). Weight gain is a situation affected by environmental and 
genetic factors (Lean ,  2003) .  There is a need for further research to advance 
the field of understanding the mechanisms of weight increase and its 
regulatory processes. 
Gender 
It is important  to examine gender when looking at weight issues because 
weight and depression have been found to be different for men and women 
(Carpenter et al. ,  2000) which then requires differences in treatment. Women 
are more interested in weight loss than men (De Souza & Ciclitira, 200 5). 
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I t  confers an up-to-date account of how as semi­
De Souza and Ciclitira (2005) in association with overweight and obesity 
considered 'health and body image' for the U. K. and found that there was a 
gender context (p.793) .  This had created difficulties for intervention since 
weight management had been seen as an area for women and homosexuals . 
According to this article , this group are the ones who recognize dieting as an 
issue. A positive aspect of this study is that it has depth of experiences from 
the homosexua l community in its constructions: this is in respect of masculine 
they do not 
experience in this area. 
identities. I t  appears that heterosexual men report less mental stress because 
'diet' but the article high lights the neglect towards men's 
structured interviews, the discourse analysis and grounded theory with a small 
sample does not allow generalization and focuses on social culture .  The 
outcome revealed issues of 'legitimacy' and 'support' (p.798 ; p. 799). I t  was 
found that men were interested 
; 
in losing weight for their health , whereas 
women had been known to desire weight loss for wanting to look good. This 
study also found that women were more caring towards men when men 
needed assistance in weight loss. Men do not acknowledge the issue of 
weight management with each other&therefore they find women understand 
better when they need to address this issue (De Souza & Cicl itira , 2005). This 
Ascher-Svanum 
is important in terms of gender and identification. 
et al. (2005) have compared men and women in their 
susceptibility to the issues of weight gain and investigated weight increase for 
their 
people with schizophrenia taking antipsychotic drugs. They found that women 
had become dissatisfied emotionally with life when their weight 
increased. A vital point made was that although there was weight gain in the 
use of antipsychotic drugs, the mental i l lness had improved, which is of 
significance but bear in mind also that the impact of how much weight was 
gained needs to be ascertained. These researchers proffer logica l ly that this 
significant improvement happened because these people are 'medication 
adherent' (Ascher-Svanum et al. , 2005, p. 1 0) .  This is an important point to 
the argument of taking antipsychotics. 
1 0  
Addington 
significance of recording weight and Body Mass Index (BMI )  of all patients on 
et al. (2003) similarly, found that there were sex differences in 
weight gain with the medications they examined and they emphasized the 
SGAs. They pointed out that they need to know the 'plateau of weight gain' 
and when this starts, as this is not known. Another good point that Addington 
et al (2003) make for reducing weight is that when implementing 'lifestyle' 
changes, it should be done relating to the needs of the group concerned 
(p .275), thus the significance of background for the population being studied 
is of value. 
It 
Obesity 
is recognized by the public that obesity , is 'stigmatized' and by contrast 
more so than other 'eating disorders' and there is 'discrimination' (Russell, 
2005 , p. 1 82). This creates d issatisfaction with one's body and feelings of 
shame for the sufferer (ibid). Indeed, the public health model advocates 
change for 'the population's environmental circumstances so that the 
susceptible individual members of the population are less liable to become 
obese' (World Health Organization - W. H. O &, 199 1 ,  p .69 ). Since , it has been 
found that obesity leads to 'the same complications' regardless of culture the 
'definitions' in this context may be applied ' universally' (WHO, 199 1 , p.69-70) . 
I f  obesity occurs there a re serious clinical implications (Zipursky et al. , 2005)  
of  Type 2 Diabetes Mellitus (T2DM) , hypertension, Cardiovascular diseases 
(CVDs) and respiratory diseases, and a number of cancers (Marder et al. 
2003;  Connolly & Kelly, 2005). Thus it is crucial that the issue of antipsychotic 
-induced weight gain should not be neglected from the outset of treatment for 
each individual. 
There have been g reat numbers of people who have become overweight in 
the western societies and in the industrialized centres of the third world during 
this past decade (Lean, 2003) .  The World Health Organization (W. H. O . )  
guidelines defines what is overweight o n  the 'basis of body mass index (BMI) ' 
which is 'BM I  = weight (Kilogram- kg) /height2 (metre2) '. (W.H .O. ,  1 99 7, cited 
in Lean, 2003, p .5 ). The components of BMI are generally adipose t issue or 
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muscle mass and the average weight range is '18-25 kg / metre2 ' ( Lean, 
2003 , p.5), and this range will help in most populations to maintain good 
health. Epidemiologically, a BMI  of greater than or equal to 30 kilogram per 
metre squared has been stated as an obese range (ibid) . It is not unusual to 
observe that there are BMls of greater than 30 depending on gender, ethnicity 
and age issues (Cooke & Wardle, 2007} . How cultural views impact on the 
individual is important; indeed the western view links excessive obesity with 
depression for women (Cooke & Wardle , 2007). Historically , women were 
desired to be fuller figured because this suggested ' ferti lity' (Dolan & 
Gitzinger, 1995,  p.2). By contrast, the 1 960's brought s limmer images, and the 
1 920s and 1 930s also presented th is image as fashionable. 
Even though there are genetic factors that predispose individuals to suffer the 
diseases associated with excess adipose tissue ( Lean, 2003) ,  it is in fact 
those who are overweight with the greatest fat distribution focussed around 
the abdominal area that are the most susceptible to diabetes and CVDs 
(Lean, 2003). I ndeed , it does not help if there is a build up of adipose tissue 
but physical activity, dieting , excess weight, smoking and too much alcohol 
are contributory factors (Lean, 2003, p .13) . There will be the drawback of 
costs associated ·with treating these problems for the health sector in future 
years if nothing is done now to prevent this crisis (Harvey et al. , 2001 ) .  
Th e  metabolic syndrome 
This era has seen a revival to investigate the association between 
antipsychotics and psychoses, with relation to the endocrine system (McIntyre 
et al. , 2005). Although research beginning in the 1970s had recommended 
that antipsychotics should be investigated further for its effects on the 
metabolism ,  such as for raised lipids (Bushe & Paton ,  2005) , it still appears 
that the interaction of antipsychotics on raised lipids needs further research 
d isorders related 
schizophrenia (Bushe & 
(Bushe & Paton, 2005)&. The impact of weight gain associated with metabolic 
generally to issues faced by those who experience 
Paton, 2005) and this has yet to be wholly 
determined for this group. In fact , there is only current, reliable data on the 
atypical antipsychotics 'olanzapine, risperidone and aripiprazole' which are 
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known to have a better cholesterol profile (p.81 ) .  Whilst the results for  other 
antipsychotics should be treated with caution because their methodologies 
have been seen to have omitted 'fasting data' and are not over long durations 
(ibid, p . 81 ) .  
1 .3 The meta-analytic studies 
This review has found schizophrenia and b ipolar I disorder (Vieta et al., 2005) 
being treated by aripiprazole. The literature review found pub lications no 
earlier than 2002 on aipiprazole (Kane et al. ,  2002)  and no later than 2008 
(Kolotkin et al, 2008 ;  Newcomer et al. , 2008) . The countries of interest in this 
review were the U. K . , European countries , U. S .A. and Asia and all the studies 
were randomised. 
Chan et al. (200 7) was an abstract of a Taiwanese population of patients, 
which examined aripiprazole and risperidone at the stage of acute 
schizophrenia. Th is study did not support the hypothesis for aripiprazole and 
weight loss in its result since there was 'mild' weight increase for the two 
groups,  with no significant difference finding . It was fortunate that this data 
was found on aripiprazole for the asian population, as studies are rare on 
a ripiprazole for this g roup, and this study highlighted no differences between 
the as ian group with the white patients (Chan et al. , 2 007,  p . 29). 
Chrzanowski et al. (2006) examined aripiprazole and o lanzapine at the stage 
of 'acute relapsing or chronic, stable schizophrenia' with results that indicated 
olanzapine had significantly g reater weight gain compared to aripiprazole at 
all time points (p.259) . This was a significant difference . 
and placebo, 
Kane et al. (2002)  was an abstract that examined aripiprazole and haloperidol 
without mentioning the stage for schizoph ren ia and 
schizoaffective disorder, and found no significant differences between weights 
for the groups. 
Kolotkin et al. (2008 ,  p. 1 )  is a secondary analysis of Kerwin et al. (2007) 
examining aripiprazole with standard of care (S. O. C. - olanzapine , quetiapine 
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and risperidone) with the hypothesis that 'patients treated with aripiprazole 
would experience fewer negative Health Related Quality of Life (HRQOL) 
consequences associated with weight change than patients treated with other 
atypical antipsychotic medications' (p.2). There was a sign ificant reduction in 
weight with aripiprazole. The results from this study may be more reliable in 
use with 'community patients with sch izophrenia' (p. 5) . The outcome, in terms 
of weight related and general quality of l ife issues , was much better for the 
aripiprazole group and for weight loss over the duration of 26 weeks. 
McQuade et al. (2004) compared aripiprazole and olanzapine with the result 
that there was a significant difference for more weight gain with olanzapine 
than aripiprazole, at the 'acute relapse' stage for schizoph renia when 
hospitalization was necessary. 
Newcomer et al. (2008) aripiprazole and olanzapine found that there was 
significant difference with weight loss for aripiprazole compared to olanzapine. 
The stage of treatment involved switching to aripiprazole after weight had 
been gained on olanzapine. There was observed to be decreases in lipid 
profile. 
Potkin et al. (2003) examined aripiprazole and risperidone and placebo found 
no significant difference with min imum increase across the groups of weight, 
during acute schizoph renia and schizoaffective disorders. The purpose of this 
study was to measure effectiveness of dosage and to assess the negative 
symptoms. 
Vieta et al. (2005) examined aripiprazole and haloperidol with no significant 
difference between these two groups at the stage of patients 'experiencing 
acute manic or mixed episodes' (p .235) . 
1 . 4  Policies 
I t  has been identified that a lack of an adequate diet can lead to early death 
and disease such as cardiovascular disease especially in the Western world, 
with est imates that it has resulted in 'over four m illion deaths per year' 
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availability , and access' (ibid) . This is necessary in the poorer countries and in 
(Robertson et al. , 2006 ,  p . 1 72) .  The importance of policies is crucial to make 
the changes for people to have better resources in 'food production, 
regions where people suffer deprivation (Robertson et al. , 2006, p. 1 72). The 
positive bearing on the community for economy is also important when 
considering policy making (WHO,  1 99 1  ) .  
In implementing change the government and 'nongovernmental organizations, 
health care workers, and the community at large' should be included (WHO, 
1 99 1 ,  p . 1 3) .  This is to communicate knowledge of food issues in relation to 
health (ibid). Informed choices are necessary when buying food and so 
labelling would also be criteria for policy making to make it easier for the 
mentally ill . 
In the past, studies that have focussed on public policy for the wellbeing of 
people's health have been in relation to 'diet, nutrition, and health ' ;  but these 
areas were not understood satisfactorily therefore the outcome was 
dissatisfaction with the policies (WHO, 1 99 1 , p. 14 ). It has been recognized 
that there are 'vulnerable groups' such as 'children, pregnant women ,  and the 
elderly' (WHO,  199 1 ,  p. 1 22) , but the mentally ill also are left out in this 
description for 'deficiency diseases' and issues around nutrition and health. 
The issues associated with mental illness and weight management appears to 
have not been attended adequately (Connolly & Kelly, 200 5) .  
It is important to give choices and th is need to be understood for the person's 
circumstances and the issue of weight management is one such area where 
the mentally ill should be supported. It is apparent that the mentally ill are 
stigmatised in society and neglected because they do not voice their concerns 
(Crisp, 2005). I t would be ideal to guide people in these circumstances with 
the appropriate counselling on nutr ition and physical activity (Connolly & Kelly, 
2005) . 
Practice issues 
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The National Institute of Cl in ical Excellence (N . I .C .E . )  (2007):46 have 
instructed that for depression , implementation of gu idel ines for grade A 
classification shou ld be from randomised controlled trials. N ICE (2007}:6 have 
suggested that those with a chronic cond ition should receive a comb ined 
treatment of med ication and persona l ised Cogn itive Behavioural Therapy 
(CBT) in  order to minim ise the long term costs of care. They a lso emphasise 
the sign ificance of defin itions because of d ifficu lties that arise for effective 
treatment plans when the theories of explanations have been so d iverse . The 
N ICE (2007) gu idel ines support practices through an evidence-base in  
relation to the varied organizational levels that support those suffering mental 
i l lnesses. 
Anti-discriminatory practice 
I n  the use of antipsychotics the Nationa l Service Framework (NSF) for mental 
health has set out pol icies to address inequal ities from the White Paper 
'Modern ising Mental Health' (Department of Health , D .O . H . ,  1 999, p . 1 ) .Th is 
supports the Nationa l Health Service to implement NSF and Nationa l institute 
for Cl in ical Excellence (N . I .C .E. )  recommendations on this issue to consider 
various assessments such as by the 'National Survey of patients' (p.2} and to 
incorporate the ·use of 'psychological therapies' as wel l  as 'decreasing su icide' 
(D .O . H . ,  1 999,  p . 1 2 ; 8) .  
The antipsychotic drugs which the patient takes should al low choice based by 
a balanced knowledge of adverse effects and the merits of taking the 
medication that involves both the patient and the doctor together (N . I .C .E .  
date). Also , the switching of antipsychotics is a possible option that the patient 
needs to know about (Schmidt, 2006) . These 'choices' along with the financial 
outlay should be made clear from the outset for the patient (Gardner et al., 
2005, p . 1 703) . This is in consideration of g iving the best treatment possib le 
(DoH,  1 999}. 
Prevention 
A preventative approach ideally for patients beginn ing treatment with atypica l  
antipsychotics would be to have a package of treatment (Littrel l  et al., 2003) 
1 6  
that i nvolves a basel ine medical assessment involving BMI and blood tests for 
risks of the metabolic syndrome (Newcomer, 2004 ; Lindenmayer et al. , 2003) 
and this should be continual ly assessed . Weight should be mon itored 
frequently i n  respect of these health issues (Undenmayer et al. ,  2003) . 
The best outcome is achieved when support is g iven to patients to advise and 
change their eating habits and encourage exercise, such as in  institutional 
and residential environments (Fau lkner et al. , 2003). A suggestion by Malhi  
(2003) is that a regime to control weight which involves regu lar exercise could 
be designed to su it the patient's requ i rements from the i n it ial consultation i n  
therapy and then consistently regu lated (p. 3) .  This i s  ideal for long term hea lth 
benefits. 
Exercise 
There are n umerous sl imming campaigns which are prominent, i n  the media, 
which impart negativity for the general publ ic because of the images of so 
cal led perfection being portrayed , but the positive benefits of sl imming are self 
esteem and wel l  being (Wadden et al. ,  2004) . Alongside n utritional 
requirements, it is  recommended that exercise is crucial to manage body 
weight as wel l '  as develop a hea lthy condition and impart wel l  being 
(Pietrobel l i  et al. , 2005). There are psychological boosts for low self-esteem 
and isolation th rough exercise (Richardson et al. , 2005) . I n  the mentally i l l  
population what has been found is that structured group programs such as 
walking can be supportive (ibid). Evidence suggests that exercise is eval uated 
as one of the best gains from treatment (Richardson et al. ,  2005) . This va lue 
of exercise has been simi lar to that in  the general population (ibid). Thus 
health professionals in th is field should also incorporate exercise i nterventions 
for people experiencing episodes of psychoses (Richardson et al. , 2005). 
Connolly and Kelly (2005) examine alternative therapy when med ications 
have exacerbated the eating habits of people, by side effects that i ncrease 
appetite, cause sluggishness and create a lack of motivation to exercise. The 
outcome of various stud ies concerning these metabolic diseases reflects that 
l ifestyle mod ification is a needed feature (Paton et al. , 2004) , and health 
1 7  
progress has been positively reported across numerous stud ies (Wadden et 
al. , 2004;)  psychologica l  advantages for this population from stud ies which 
review benefits of exercise and d iet a longside counsel l ing for long-term weight 
maintenance (Faulkner et al., 2003) 
Suicide 
Carpenter et a/'s (2000) work on gender d ifferences found that suicidal 
tendencies were more l ikely amongst the normal  weight men , because of 
body image dissatisfaction , compared to obese men; and even more intense 
depression and suicide issues were found when men were underweight. 
Women on the other hand behaved suicida l when obese and were more 
balanced emotionally when they were underweight and normal weight. Thus 
weight gain is a problem as research has identified in that the negative 
psychological impact of neglecting overweight issues may lead to loss of 
image, isolation,  and even suicide (Carpenter, et al. , 2000). The interventions 
for the mental ly i l l  group are even more d ifficult (Paton et al., 2004) not just 
because of their negative lifestyles but because of the prevalence of comorbid 
i l lnesses and diagnosis such as those known for sch izophrenia (Connol ly & 
Kel ly, 2 005) . 
Self-esteem 
Self-esteem is pivotal i n  every individual 's mental framework for coping 
healthi ly and it appears that a low self-esteem indicates a dysfunctional 
mindset (Fox, 1 999) . Low self -esteem is one of the problems that can arise 
from obesity .  Wadden et al (2004) found that obese patients with a BMI of 
over or equal to 40 kg per metre square, had significantly greater depressive 
symptoms and significantly lower self-esteem than those with a BMI less than 
40 kg per metre square. Research seems to imply that as a result of ensuing 
health issues and suffering prejudice and discrimination, people who are 
obese become depressed (Fabricatore & Wadden, 2003) and obesity may 
occur over a period of time as food is consistently sought for as source of 
comfort to replace human contact (Fabricatore & Wadden , 2003). 
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weight because of the use of medications, and this should not be ignored, 
likewise for the mentally healthy groups. 
Fabricatore and Wadden (2003) have examined prejudice and discrimination 
as causes of depression and other emotional problems in obesity, even 
though the relationship between depression disorders and obesity is unclear 
(Cooke & Wardle, 2007 )&; it appears that the societal impressions of slimness 
is so portrayed that it undermines healthy behaviours psychologically. 
Although there is known to be weight gain with most antipsychotics 
(Newcomer, 2004)&, the effects of weight gain is important to acknowledge 
because of the profound implications for self-management when suffering 
mental i llness (Richardson et al. ,  2005)&. Wadden et al. (2004) compared 'self­
esteem , and body image' for women, in weight management amongst the 
mentally healthy population (p.56 1 ) .  They gave counselling for lifestyle 
change surrounding the issues such as 'control' and found that the 
participants were better in their 'body image and self-esteem' even when they 
did not lose weight. 
The importance of body image is also vital to the mentally ill population as 
researched by Weil et al. (2002) who found that people with a mental illness 
were interested in losing weight 'more frequently than the general population' 
(p. 1 267)&. This research done in the United States , found that obesity was 
higher in this group than for the mentally healthy groups. A high proportion of 
people with disabilities desired to lose weight and embarked on 'exercise 
counselling' (p. 1 267 ). Weil et al. (2002) pointed out that their outcomes were 
similar to previous studies which revealed 'an association between obesity 
and disabi l ity' issues (p. 1267) . This population is susceptible to increases in 
The purpose of this review is to explore whether there is weight loss in 
patients taking the atypical antipsychotic, aripiprazole. There is a lso the 
underlying aim to g ive support to those suffering mental illness in regard to 
treatment and identify the ways in which further exploration of these findings 
could improve their health and well-being psycholog ically. The impact of 
weight management within this population is also being examined because it 
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is known to facilitate improvements in long-term health, through support that 
relates to self-esteem. There was less literature on the issues of weight gain 
and aripiprazole, since as recent drug for mental illness it has not yet had 
extensive research and there have been good expectations (Naber & 
Lambert, 2004) . 
2.0 Aim 
To conduct a meta-analysis on eight primary stud ies to investigate the atypical 
antipsychotic, aripiprazole , compared with a few other antipsychotics in the 
treatment of mental i llness for weight loss. 
2 . 1  Objective 
Primary objective : to explore the effects of aripiprazole and weight loss 
compared with other antipsychotics for people with a mental illness both 
psychologically and with regard to a benefit in weight management. 
2.2 Hypothesis 
To determine whether aripiprazole, as an atypical antipsychotic ,  has an effect 
on weight loss compared to other antipsychotics .  
3. Criteria for considering studies for th is review 
3. 1 Types of studies 
Initially only relevant randomised controlled trials were selected. Then after 
narrowing down the field , only studies where criteria for meta-analysis was 
possible were collated, for all types of designs, due to limitations of the 
number of stud ies available because this area of interest involves a relatively 
new medication (aripiprazole) , on the market and there is less research on it 
at the moment. 
3 . 2  Types of participants 
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People with schizophrenia and schizophrenia spectrum disorders, were 
accepted to start with, and then it became all psychoses and mental illness, 
defined with a respectable well known diagnostic criteria. This population 
consisted of all people between the ages 1 8-65, not excluding race or gender. 
I llness was over any length of time and t reatment in any setting . 
3.3 Types of intervention 
The comparison of all antipsychotics for weight gain or weight loss across all 
single and g roups of meta-analytic reviews were found.  Next, further searches 
focused on the atypical antipsychotic aripiprazole, because as a newer drug it 
was purported to be more effective in producing less weight gain than other 
antipsychotics. Thus the primary outcome had to be weight loss in the 
included studies for the support of the hypothesis and then only single reviews 
were sought. 
a) Aripiprazole: oral doses ranged from 1 0  - 30 mg/day. 
b) Standard of Care (S .O . C. ) :  olanzap ine (5-2 0  mg/day) risperidone (2-8 
mg/day) , quetiapine ( 1 00-800mg/day). Other antipsychot ics: Haloperidol 
( 1 0mg/day). Atypical antipsychotics: Risperidone (6mg/day) . Olanzapine ( 1 0-
20mg/day) . 
3.4 Types of outcome measures 
3.4. 1 Adverse effects of weight gain. The weight was measured in kilograms 
(mean change in body weight from baseline), mean BMI ( Kolotkin et al. , 2008) 
or seen as a probability p value (Kane et al. , 2002) . The period of outcome 
measures for weight gain was defined as 1 2  weeks or less for short term, 
medium term was 1 2-52 weeks and long term was over 52 weeks (or over 
one year) (Duggan et al. ,  2005, p .3). 
4. Search methods for identification of stud ies 
4. 1 The search strategy involved the electronic databases of the Cochrane 
Collaboration/L ibrary. The searches were done for any year by using the 
keywords schizophrenia, weight gain, and random controlled trials. Then, the 
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keywords antipsychotics and weight gain were tried , a longside aripiprazole 
and weight loss and a lso for the health care databases of the d ig ital l ibrary of 
AMED (a lternative med icine) , Med l ine via Ebscohost Research Databases, 
Med l ine through PubMed, Ebscohost EJS (Electronic Journals Service) , 
Ebscohost RD (Research database) , C INAHL Plus with fu ll text, SoclNDEX 
with fu l l  text, Psych I nfo, Scirus for scientific information , l ntute, Sage premier, 
B iolog ical and b iomed ical sciences databases that led to B iomed central and 
the National l ibrary for health. 
Searches were also done using the keywords: arip iprazole and weight gain or 
weight loss , aripiprazole and atypical antipsychotics and weight loss , with any 
of my search terms to be found with fu l l  text or abstracts. The other keywords 
a lso tried were psychologica l  impact, weight management, metabol ic 
d isturbances, and metabol ic syndrome. 
4 .2  The l iterature search included conference papers, journals ,  e lectron ic 
journa ls, research report reference l ists, research b ibl iographies, a longside 
reference databases (such as Psych I nfo) .  
5. Methods of the review 
5 . 1  Methods. 
Al l the designs were randomised ; duration of the stud ies ranged between 4 
weeks to 52 weeks; therefore average duration was 1 8  weeks. The doub le­
bl ind reflects cu rrent practices of evidence-based medicine that is preferred to 
avoid ' bias' (Steptoe , 2007, p .355). Doub le-bl ind is a strategy that a ims to 
avoid knowledge of the treatment cond itions for both the experimenter and the 
participant so that the outcome i s  not affected by their personal influences 
( ib id) .  
5 .2 Participants and setting . 
Al l studies included people d iagnosed with schizophrenia or schizoaffective 
d isorders and Bipolar I disorder. The majority stated the DSM-IV criteria for 
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diagnoses, and in only one study the diagnostic criteria was not reported 
(Chrzanowski et al. , 2006) but appropriate measures were applied for mental 
and 'Clinical Global Impression Improvement scale (CGl-I) '  and scales of 
'Positive and Negative Syndrome Scale (PANSS)' for schizophrenia 
(Chrzanowski et al. ,  2006 , p .260). 
The studies were examining the participants at the stages of 'acute, relapsing 
or chronic, stable schizophrenia' (Chrzanowski et al. ,  2006,  p.259) ; 'acute 
schizophrenia' (C han et al. , 2007, p .29) ; 'acute relapse' for 'hospitalization' for 
schizophrenia (McQuade et al. ,  2004 , p.47) ; 'acute exacerabation or 
sch izophrenia or schizoaffective disorder' (Potkin et al. , 2003 ,  p.68 1 )  or at a 
stage of switch ing medication for schizophrenia (Newcomer et al. , 2008)&; and 
for 'acute manic or mixed episodes' of Bipolar I disorder (Vieta et al. ,  2005, 
p.235) . There were slightly more male than female participants in Kolotkin et 
al. (2008) and Chrzanowski et al. (2006) whereas in the other stud ies the 
percentage was not stated either in the full article or the abstract. The 
participants were aged between 1 8  - 65 (Potkin et al. , 2003 ;  Vieta et al. , 
2005) with a mean age of 38 .5 years in Kolotkin et al. , (2008) and data for the 
other studies were not provided (Kane et al. ,  2002 ;  C han et al. ,  2007; 
McQuade et al. ;  2004; Newcomer et al. ,  2008; Chrzanowski et al. ,  2006) .  The 
mean BMI of the participants at baseline was provided in Kolotkin et al. 
(2008) ; the mean weight of the participants at baseline was approximately 
74.6 kg with a standard error of 1.&1 for aripiprazole (Vieta et al. ,  2005, p.247). 
5. 3 Setting. 
Four studies included only outpatients (Chrzanowski et al. ,  2006&; Chan et al. , 
2007; Kolotkin et al. , 2008; Newcomer et al. , 2008; ) ,  three studies included 
only inpatients ( Kane et al. , 2002:  McQuade et al. , 2004; Potkin et al. , 2003 ; )  
and one involved both (Vieta et  al. , 2005). 
5.4 Study size. 
Most studies were large and ranged between 83 - 555 participants at the start 
of the study (mean number randomized 31 3)&. The total number of participants 
from the eight studies were N = 2, 507. 
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5 . 5  I nterventions.  
The studies were comparisons for aripiprazole, with a control group for S.O.C.  
(Kolotkin et al. , 2008), risperidone (Chan et al. , 2007; Potkin et al. ,  2003), 
olanzapine (Chrzanowski et al. , 2006; McQuade et al., 2004 ;  Newcomer et al. , 
2008) and ha loperidol (Kane et al. , 2002 ; Vieta et al, 2005). 
5 .6 .  Selection of trials 
This was done by carefu l examination of al l  research articles , with titles and 
abstracts being read first before accessing the fu l l  article for further 
investigation. Then the decision to accept the studies was considered if the 
criteria for inclusion were met for the review in the methods section. 
5.7 Data col lection .  
The data from the selected studies were extracted with regard to use of the 
statistical method of meta-analysis. 
5.8. Data synthesis .  
Calcu lations were done using the formulae from Rosentha l  ( 1 978). The p 
value and z scores on the Gaussian curve have a normal distribution of data 
here, and this method was appl ied for a l l  the included primary studies . 
5 .9 Incomplete data. 
There a re high rates of discontinuation in this area, but studies were not 
excluded on the basis of the percentage of participants completing them . 
6.  Description of studies 
The fol lowing tables summarise the information for the studies that were 
suitab le for the meta-analyses and those that were rejected. 
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6 .1 Included studies 
Table 1 Table of included stud ies 
Authors 
Chan ,  L in ,  L in ,  Hwang, 
Su ,  Ch iang & Hwu 
(2007) 
Chrzanowski ,  Marcus ,  
Torbeyns ,  Nyi las & 
McQuade (2006) 
i 
Kane, Carson ,  Saha,  
McQuade , I ngenito, 
Zimbroff & Ali (2002) 
Ko lotk in ,  
. Corey-Lisle ,  Kan & 
i McQuade (2008) 
McQuade , Stock, 
Marcus, Jody , 
Gharbia, Vanveggel ,  
Arch ibald & Carson 
(2004) 
Newcomer , Campos, 
Marcus, Breder, 
Berman,  Kerselaers, 
L' ita l ien ,  N ys ,  Carson 
& McQuade (2008) 
Method 
Randomised 
Dou ble bl ind 
Randomised 
Double b l ind 
Randomised 
Double b l ind 
Randomised 
Randomised 
Double b l ind 
. Randomised 
Double bl ind 
Condition 
Schizophren ia 
o r  
sch izoaffective 
disorder 
sch izophren ia 
Sch izophren ia 
or  
sch izoaffective 
d isorder 
Schizophren ia 
' 
Sch izophren ia 
' Schizophrenia 
or 
sch izoaffective 
d isorder  
No. of 
partic i  
-pants 
83 
2 1 4  
: 4 1 4  
555 
3 1 7  
1 73 
Weight findings 
! 
No s ign i ficant d ifference 
with m i ld weight ga in  for 
both arip iprazo le and 
risperidone.  
Olanzapine had 
sign ifican tly g reater weight 
gain compared to 
arip iprazole at all t ime 
points. At week 52 [LOCF] :  
: +2 . 54 vs . + 0 .04 kg; p< 
0 .001 
No  s ign ificant d ifferences 
with weight. 
P < ore . 05 = 
Sign ificant reduction  with 
aripi razole P< .05 
More s ign ifican t  weight ga in 
for o lanzapine (37%) 
compared with ari p i p razole 
( 1 4%) .  p<  .001 
S ign ificant we ight loss for 
arip iprazole (>eOre= 7%) 
compared to olanzap ine 
{ 1 1 . 1 % vs. 9 . 1 % e; p =  .082 ) 
Potk in ,  Anutosh,  Saha, Randomised Schizoph ren ia Not sure if there is a 
Kujawa, Carson ,  A l i ,  Double bl ind 
Stock, Stringfel low, 
or  sign ificant  i ncrease in  
weight for arip iprazole. Schizoaffective 
I ngenito & Marder 
{2003) 
Vieta , Bour in ,  
Sanchez, Marcus ,  
Stock, McQuade, 
Carson ,  Abou-
Gharbia ,  Swan ink & 
Iwamoto {2005) 
Double b l ind 
Control led 
comparison 
of 
Arip ip razo!e 
and 
Haloperidol 
. F ixed 1 : 1  
I Ratio 
d isorders. 
Bipolar I 347 
d isorder with 
acute or  mixed 
ep isode 
' 
Min imum increase across 
{not s ign ificant) -1 .2kg,  
0 .8kg ,  1 . 5kg . But sign ificant  
d ifference to  placebo. t-
tests for placebo vs 
aripiprazole or ch i square .  
No sign ificant d ifference 
between ari piprazole and 
haloperido l .  
No s ign ificant d ifference i n  
Arip iprazole (+0 .27Kg )  
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6 . 2  Excluded studies . 
Table 2 Table of excluded studies .  
! I 
Authors Method I Condition 
Karunakaran ,  Randomised Schizophren ia 
Tungaraza & 
Harborne (2007) 
·- ·--
Keck Jr. , Marcus ,  Randomised Bipolar I 
Tourkodimittris, Al i ,  Double bl ind d isorder 
Liebeskind, Sah  & 
ingenito (2003) 
·- -
Kerwin ,  Mi l let, Randomised Sch izophrenia 
Herman ,  Bank i ,  
Lub l in , Pans ,  
Hanssens ,  L ' l ta l ien ,  
McQuade & Beuzen 
�· (20071 - - - ·--- "-
McElroy, Suppes, Prospective Bipolar I 
Frye, d isorder 
Altshuler, Stanford , 
Martens, Leverich , 
Post & Keck J r  
, (2007) 
Sachs, Sanchez. Aripiprazole Bipolar I 
Marcus, Stock, VS. Placebo d isorder 
McQuade, Carson ,  
Abou-Gharb ia ,  
lmpell izzeri, Ka plita , 
Rol l i n  & Iwamoto 
(2006) 
I 
I - -·· -
No. of 
partici-
pants 
26 
, 
262 
555 
I
! 
31  
272 
!Weight find ings 
and reason for exclusion 
S ig n ificant weight loss 95 . 3  
kg to 90 .2 kg . p= .002,  z =  -
2 58 N=20 
Excluded because this is a 
review of case notes. 
Non s ign ifican t  weight gain . 
-0 .3 kg small weight loss for 
a ripiprazole , N =  1 30 ,  
z= 1 30 ,  z=0 p< .5 .  sl ig h t  
decrease i n  both -. 8 for  
placebo. N on sign ificant. 
Excluded because i t is a 
_pl§c::ebo controlled study _ 
Same data as Kolotk in et 7' 
al. (2008) ! 
Excluded because repl ica 
data of Kolotk in et al. 
(2008) . 
Weigh t  ga in is for 
ar ipiprazole on ly .  t= 1 .  95 df 
26 p= .06 ,  z= 1 .6?, p= . 9  p>. 5 
cohen d= .76 .  Very non 
sign ificant. 
Exc luded because it is  a 
placebo con trol led studv. I 
Non s ign ificant  weight ga in .  
Smal l  weight ga in . 53kg . 
Decreased ( < .6kg) n= 1 37 
(aripiprazole ) ,  ne 1 35 = 
(placebo) ,  non significant 
reduction p< .5 ,  p=. 5 , z=0 . 
No specific sign ificant test. 
Excluded because it is a 
placebo con trolled studye _  .__ 
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7. Methodolog ical qual ity 
7 . 1 Randomisation 
The eight stud ies chosen for meta-analysis used random al location .  
7.2 Bl inding 
There were seven stud ies that were double-b l inded (Chan et al., 2007; 
Chrzanowski et al. , 2006 ; Kane et al. , 2002; Potki n  et al. , 2003; McQuade et 
al. , 2004; Newcomer et al. , 2008; Vieta et al. , 2005) and one study that did not 
state method of bl ind ing (Kolotkin  et al. , 2008) . 
7 .3  D iscontinuation 
There were people leaving the study early in Kolotkin  et al. (2008) due to s ide 
effects (20 . 1 % for aripiprazole and 1 5. 9% for S .O .C . )  and at the end of the 
study at week 26 the figure for those sti l l  participating was 60% (p.5) .  There 
were 1 62 out of the orig inal  404 pa rticipants who discont inued in  Potkin  et al. 
(2003} with main reasons such as inadequate cl in ical treatment or becoming 
psychotic (not related to study reg ime) . Chrzanowski et al. (2006) had least 
number of participants leaving the study early (69 % remained} because of 
'withd rawal of consent' (p. 26 1 ) . It is not reported in Chan et al. (2007) or 
Kane et al. (2002) of any numbers leaving the study early (they are abstracts 
only i ncluded studies) .  There were large numbers of dropouts in  Vieta et al. 
(2005) as wel l ,  with 59.9% and the reason g iven was for side effects again 
such as EPS (p .238). Other reasons were l isted as 'patient withd rawal of 
consent (6 . 1  %) and lack of efficacy (5.2%)' also l iver damage ' re lated to study 
med ication' (p. 239; p .238). The numbers of people leaving for a l l  the 
remaining studies were unclear as in the abstracts only included stud ies 
(McQuade et al., 2004,  Newcomer et al. , 2008). 
7 .4 .  Data reporting 
Potkin et al. (2003) presented data in  g raph form as a boxplot which indicated 
that there were also 'p ' values .  Vieta et al. (2005) gave graphs to depict 
changes and tab les of demographic information; and various measures for 
27 
assessments such as 'efficacy' and 'depression ratings '  (p. 237; 238); also 
analyses that used the Last Observation Carried Forward (LOCF) analysis 
which are 'observed cases, defined as those completing the trial' ( ref.) and 
observed cases data- sets for results (p.236) . Percentages were given and 
body weight in kilograms and means with standard error from baseline in 
Vieta et al. (2005;  Newcomer et al. ,  2008; Kolotkin et al. ,  2008 ; Chrzanowski 
et al. ,  2006;  McQuade et al. (2004) reported data in k ilograms, pounds and 
percentages with 'p ' values. Chan et al. (2007) and Kane et al. (2002) gave 
significant levels with 'p' values. 
7.5 Overal l quality 
The methodological quality of included trials in this review was done by 
following guidelines described in the Coch rane Handbook (2008) . The 
hypothesis was important in choosing the studies and then to understand the 
bias in the methods for reliability (H unter & Schmidt, 2004) . In the assessment 
of quality there may be l imitations encountered that does not accept the 
studies, and may lead to reject a study. There were five studies (Karunakaran 
et al. ,  2006 ; Keck et al. , 2003; Kerwin et al. , 2007; McElroy et al. ,  2007; Sachs 
et al. ,  2006) that were rejected. There was s imilarity seen across the studies 
with similar researchers, because they were involved in second studies as 
members of a g roup such the 'S.T.A. R. '  (Schizophrenia Tria l of Aripiprazole) 
(Kolotkin et al. ,  2008). 
The included studies were good because the methodology p rovided results for 
them that were different f rom the excluded studies which had been judged as 
bad choices , with differences between them that allowed rejected (H unter & 
Schmidt , 2004 ) .  The issue of limitations in the method is important in 
evaluating the quality for the overall results of the meta-analysis (Hunter & 
Schmidt , 2004). It is stated that meta-analysis may "mix apples and oranges" 
(for example atypicals and typicals such as aripiprazole with haloperidol ) i n  
the outcomes, though th is may mean seem to complicate matters ,  i f  each 
case is p resented with its outcomes separately then the regardless of the 
strangeness of this concept this issue can be interpreted (H unter & Schmidt , 
2004 , p.469). 
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The possibi l ity of bias i n  the i ncluded studies 
1 .  Randomisation. 
All the studies were reported as randomised. 
However half of the included studies did explicitly describe the methods 
section with inclusion a nd exclusion criteria. Although, for the other half of the 
included studies this was difficult to know because they were abstracts only. 
2. Blindness. 
There was only one study that did not state blinding and this was a secondary 
study (Kolotkin et al. ,  2008). The participants are blinded to prevent losing 
them from the study and to avoid i nfluencing the results by giving away any 
knowledge of the areas being investigated (Christensen ,  2004) .  
3 .  Loss to follow up 
None of the included studies mention a follow-up over their losses except 
Potkin et al. (2003) which comments on a follow up being done that needs to 
be longer , because of taking weight measurements that represent consistent 
findings (p. 690 ) :  
4. Data reporting 
The data was fairly well reported in the included studies; and those that could 
not be used were outcomes that were often presented as graphs , or just 
reported as inexact p-values (Keck at al. ,  2003) . 
This systematic review sought general information from the t itle , authors (such 
as those in a group studying the same issues) , publication date - generally 
recent i n  this case, type of intervention which needed to include aripiprazole,  
and the presence of a meta-analysis . The title and abstracts were first read to 
assess whether the study was relevant for meta-analys is .  Then the 
introduction led the approach for the systematic literature review, with the 
resu lts next for the p values to cond uct a meta-ana lys is .  Then an evaluation of 
what the authors reported in the methods section of their  review was done for 
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threats 
'cause and effect' design (Christensen , 2004 ,  p.&1&98) .  This 
requirement is not possible in this case since it is possible that there are 
'extraneous variables' acting on the weight outcome other than the medication 
qual ity assessment. This included whether the authors revealed that they had 
made quality assessments and by what methods this was done, such as a 
scale or checklist as in the criter ia for exclusions,  for instance (Kolotk i n  et al. , 
2008) .  It is not known if each study carried out a quality assessment but DSM 
criteria for assessment of disorders was present and this indicated good 
quality. 
Random Controlled Trials's (RCTs) are observed as the most objective 
method of removing bias by choosing a sample by chance and it takes 
account of the variability of the participants ( McQueen & Knussen, 2002 ). 
Random sampling does not require in depth details of the population under 
investigation to make a generalisation ( McQueen & Knussen, 2002). RCTs 
randomly allocate participants into a control group and an intervention group, 
Public 
with the two groups being identical for any significant variab les ( Christensen ,  
2004) . They should be  followed up  for their specific outcomes ( ibid) .  
health is less well suited to RCTs because it believes in evidence based 
practices and RCTs are slow and expensive producing results that can be 
difficult to apply to real situations ( (McQueen & Knussen, 2002). In fact RCTs 
may l imit generalisations to geographical demographics, known as 'area 
sampling' (McQueen & Knussen, 2002 ,  p.73) .  Thus this could be an issue of 
selection bias. 
This review gives to internal validity. I n ternal validity is the 
understanding that 'only' the independent variable impacted on the dependent 
variable in a 
(ibid . p. 1 99) . Therefore a causal inference cannot be made in this review. 
Internal validity is the 'extent to which systematic error (b ias) is minimised in 
clinical trials' and this is affected by 'selection b ias, performance bias, 
detection bias, and attrition bias' (Juni et al.&, 200 1 ,  p .1 )  Attrition bias is 'biased 
occurrence and handling of deviations  from protocol and loss to follow up' 
( ibid , p .1 ). 
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The scales had been cleared every time for a weighing and the same scales 
were used every time thus there was a standardised procedure (Kolotkin et 
al. , 200 8) .  In this case the weighing of the participants should all be of the 
same procedure as well as the definitions for the scales of measurements for 
their mental health and weights .  The qualifications of the researchers is 
important in the treatment interventions being g iven because of the serious 
clinical nature of the issues being dealt with ,  and their abil ity to give an 
objective and reliable method of measure is also referred to as 
standardisation (Coolican, 1990). This is  important because it makes the trials 
the same for everyone by adjusting it using reliab ility and validity tests (C legg, 
1990, p.42) . This is of 'scientific and ethical importance' (Coolican, 1 990 , 
p.11 3). It is important to consider other variables in order to red uce bias. 
Validity and reliability are affected by researcher bias (Christensen, 2004) . l n  
evaluating the quality of the review, risks of bias may be found. 
8. Results 
8. 1. Included studies. 
There were eight studies that were included, wh ich reflected the hypothesis 
well. The studies had included the S .O .C. drugs of olanzapine, risperidone, 
quetiapine, as well as the antipsychotic, haloperidol and the atypical 
antipsychotic, a ripiprazole. The psychoses were included along with a ll menta l 
illnesses that were being treated by the drug aripiprazole effectively, such as 
bipolar 1 depression (Vieta et al., 2005) , sch izophrenia and schizophrenia 
spectrum disorders. The focus was weight management for this population 
and included weight loss or weight gain. The designs were all Randomised 
Controlled Trials (RCT's), and the articles were publ ished from 2002 to 200 8 ,  
wh ich highlights that this drug is new and it is an effective agent in the 
treatment of psychoses and mental illness. The characteristics of these eight 
included studies are seen in append ix 2 .  
8.2 Excluded studies 
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The characteristics of excluded studies are seen in the appendix 3. Studies 
were excluded on basis of age - over 65s , placebo, comorbidity, under 1 8, 
learning disabil ity ,  single case history stud ies, and the add it ion of chemical 
compounds such as s ibutramine and fluoxetine for weight loss (Faulkner et 
al. ,  2007, p . 1 2) .  Five studies were excluded from the meta-analyses (Kerwin 
et al. , 2007 ,  McElroy et al. ,  2007&, Karunakaran et al. , 2007 , Keck Jr. et al. , 
2003, Sachs et al. 2006) .  Kerwin et al. (2007) was rejected because it 
rep licated the findings of Kolotkin et al. (20 08) and it was an earlier study. 
McElroy et al. (200 7) was rejected because it was examining aripiprazole only 
for weight gain and there were no other comparators. Sach&et al (2006) was a 
non-significant reduction at p > . 5  value but it was comparing with a placebo 
which was an exclusion factor and there was no specific significant test. 
Whereas Keck et al. (2003) indicated small a weight loss over three weeks 
with aripiprazole being at -.3 kg and this was not signif icant at p< .5 value , but 
it was comparing with a placebo as well. Finally, Karunakaran et al. (2006)  
had a significant weight loss at p = .002 with a z = -2. 58,  but this was a review 
of cases and thus excluded. 
8.3 The meta-analysis found that most of the eight studies were between 4 
and 52 weeks (short term and medium term) , and indicated that weight loss is 
ach ieved and it seems that aripiprazole has beneficial and less problematic 
s ide effects (Naber & Lambert, 2004). Similar to other atypical agents it 
causes less extrapyramidal effects symptoms, and in contrast it seems to 
prevent some of 'the metabolic and cardiac side effects' (Naber & Lambert, 
2004 ,  p.1217) . 
There was not enough information to test issues of race and gender as well 
because only the abstracts were available in some cases. In testing the one­
tailed hypothesis  for aripiprazole with other antipsychotics, the meta-analysis  
was calculated with Rosenthal's formulae. There are various methods in 
meta-analysis but  in this review the method used is of  cumulative values of p 
seen through similar studies with the same question in mind (Hunter & 
Schmidt, 2004) .  The statist ical s ignificance of the hypothesis is being tested. 
The null hypothesis needs to be known for being true or false in this case and 
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the error rate can be defined (Hunter & Schmidt, 2004) . Generally the 5% rate 
is the ideal for significance testing with sample sizes, but this applies 
specifically when the null hypothesis is true (Hunter & Schmidt, 2004) thus 
values of p are termed significant or not for the hypothesis. The overall 
statistical significance level (p value) for the eight studies have cumulating p 
values across these studies , and for an assumed null hypothesis finding z=0 
was assigned in some instances. Fisher ( 1932 , in Hunter & Schmidt , 2 004, p. 
453) in significance testing of the null hypothesis has provided the F -test for 
small numbers in a population, as seen in some of the studies, with a 
parametric , Gaussian curve for p values and z values for significance. 
Rosenthal (1978a) has been interested in the signif icance level with p value in 
one-tailed tests where this has to be 'converted to a standardized normal 
deviate ,  denoted z' (cited in Hunter & Schmidt ,  2004, p.447 ) . The z values 
have been 'either summed directly or used to compute a weighted sum of the 
zs' (ibid, p.447). Then the average of these zs is computed and the 
significance level (p value) of the average z value is determined. This is the p 
value for the set of studies as a whole' (ib id, p .447 ). This is a fixed-effects 
model and applies the method of a 'partially hierarchical breakdown '  (Hunte r  & 
Schmidt, 2004; · 447, 424) . Fisher ( 1932) too has recommended this method 
(in Hunter & Schmidt, 2004 ,  p.453) . 
The data was of continuous type and normally distributed, though data on 
clinical and social outcomes are not normally distributed (ref.). The change 
data (endpoint minus baseline) and endpoint data were recorded. I t  was 
expected that aripiprazole would be lower at time 2 (T 2) for weight than other 
d rugs to support the hypothesis, by showing a difference between the 
comparison drug and aripiprazole for effect. The studies showed body weight 
in kilograms or a change from baseline to endpoint also BMI  was given in 
some cases and means. In some instances the study lacks specific data for 
the statistical calculation so assumptions have been made for a valid meta­
analysis. 
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Effects of i nterventions 
Only abstracts were available for 4 studies (Chan et al., 2007, Kane et al. ,  
2002 ,  McQuade et al. , 2004 & Newcomer et al. ,  2008). The search strategy 
identified 15  studies. Of these 13 potentially relevant trials were selected. 
Included were eight studies and seven studies were excluded. 
8 .3 .1 Chrzanowski et al. (2006) aripiprazole versus olanzapine, at 2 8  weeks 
duration (medium term) 
Weight: Olanzapine had increased weight at all points in time than 
aripiprazole (week 52 [LOCF] : +2 . 54 vs +0.04 kg ; p < 0.001). 
=The statistics were calculated using tables, N1 = 71 , N2 8 9  (Total N=1 60) , 
p< .0 1 ,  to produce the value of z = -2 . 3 3. 
8. 3 .2 McQuade et al. (2004) aripiprazole versus olanzapine , at 26 weeks 
duration (medium term) 
Weight: 37% of olanzapine had significant weight gain versus 14% of 
aripiprazole . 
This was statistically calculated by p<. 00 1 and total N=3 17, with z=-3.00. 
8 . 3 . 3  Newcomer et al. (2008) aripiprazole versus olanzapine, at 1 6  weeks 
duration (medium term) 
Weight: Greater proportion of participants on aripiprazole had weight loss (> 
or = 7%) versus olanzapine (1 1. 1 % vs. 2.6%; p= . 03 8 ) . 
=Total N& 173 , Aripiprazole N = 8 8 , olanzapine N = 85 , at 16 weeks weight 
decreased significantly with aripiprazole versus olanzapine p< .001&, z= - 3.00 
8 .3&.4 Chan et al. (2007), aripiprazole versus risperidone, at 4 weeks duration 
(short term) 
Weight : There was a minimal weight gain for both aripiprazole and 
risperidone. 
= =Total N& 83, aripiprazole n= = 49, Resperidone n& 34, z was given a value z= 
0 .00 and there was no significant difference and both would gain .  An 
assumed null finding of z=0. 
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8.3.5 Kane et al. (2002) arip iprazole versus haloperidol (against placebo) , at 4 
weeks duration (short term) 
Weight: There was found to be 'no statistically significant differences in mean 
changes in body weight across the treatment groups versus placebo' (Kane, 
2002, p . 1 )  
Assumed N=2 76 ,  aripiprazole n= 1 38 ,  haloperidol n= 138 ,  placebo n= 1 38 ,  z 
is given value z=0 .00. An assumed null finding of z=0. No significant 
difference (assumed n is 4 1 4/3 for each group) .  
z = 0.000 
8.3.6 Kolotkin et al. (2008). The result is taken from Kerwin et al (2007 ) .  
Aripiprazole versus Standard of Sare (S. O.C.) , at 8 weeks duration (short 
term). 
Weight: Over the entire 2 6  weeks duration there was decreased weight for 
aripiprazole treated patients compared to S.O. C .  
N= 555, z= -7.5, p< .000000 
t= - 7.5. Interaction F= 25. 98 
(3 , 1 1 46) p< .  000 1  
N=278 , -1.45% : P=0.05 ,  z=-1 .65. Significant reduction p < .  05 
A t-test of difference was done for this at 0 .05 and the t value was square root 
of 56 t=7 .5. A complex interaction was reported - Aripiprazole versus. S .O .C 
a three time follow up .  Also reported contingency table chi significant weight 
gain/loss z= -4 .6 p<. 001 .  
8 .3.7 Potkin et al. (2003) Arip iprazole versus resperidone. 
Weight: Not sure if there is a significant increase in weight for arip iprazole . 
Minimum increase across (not significant) - 1. 2kg , .8kg, 1. 5kg but significant 
difference to placebo. 
t -tests for placebo versus aripiprazole or chi square. 
N=1 00 
Z=0 
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placebo 
=N=300 , aripiprazole n= 101 + 100, resperidone n& 99, N = 300 , n = 404/3 , no 
significant difference z=0.00, this was an assumed null hypothesis finding of 
z=0. 
8. 3.8 Vieta et al. (2005) aripiprazole versus haloperidol , at 1 2  weeks duration 
(short term) 
Weight: No significant difference between aripiprazole versus haloperidol. 
No significant difference in aripiprazole +. 27 kg z=0 ,  N=174 
= =N& 347 ,  z& +0. 50 
n = 17 5 versus n= 17 2 ,  therefore total N = 347 
8 .4 Table of analyses. 
The following table summarises the analysis of the results. 
Study 
Chrzanowski et Aripiprazole vs. 
al. (2006) olanzapine 
Kane et al. (2002) . Aripiprazole vs. 
Haloperidol vs. 
Ko lotkin et al. Aripiprazole vs. 
(2008) S .O .C. 
: 
T bi 3 T bi fa e a e o ana 1yses 
Desig n 
Chan et al. Aripiprazole vs .  
(2007) risperidone 
Arip iprazole vs . 
ha loperidol 
Results Sample s ize 
No s ign ificant N=e83  
d ifference 
P < . 0 1  N=e2 1 4  
Sign ificance 
d ifference 
No s ign ificant N=4 1 4  
d ifference 
P< ore= . 05 
t =-7 .5  N=555 
F= 25 .98 
p = 0 .05 
p < . 000 1 
S ign ificant 
! d ifference : 
P<e. 00 1  N=  3 1 7  
Sign ificant 
d ifference 
P < .001 N= 1 73 
Sign ificant 
d ifference 
No sign ificant N=e404 
d ifference 
No sign ificant N=  347 
d ifference 
Estimated z 
va lue 
Z = 0 assu med 
nu l l 
: 
Z =-2 .33 
Z = 0 . 000 
assumed nu l l  
Z = -7 . 5  
- 1e.45% resu lt 
from Kerwin et 
al. (2007) - an  
earl ier study 
Z= -1 .65 
Z= -3.00 
Z = -3 .00 
Z= 0 assumed 
nu l l  
Z = + 0 . 50 
: 
I 
McQuade et al. Aripiprazole vs . 
(2004) o lanzapine 
Newcomer et al. Aripiprazole vs. 
(2008) olanzapine 
Potk in  et al. Arip iprazole vs. 
(2008) risperidone vs. 
: placebo 
Vieta et al. (2005) 
8 .4 Rosenthal (1 97 8) formula was applied for a statistical method for data 
analysis in meta-analysis for the included eight studies. I t  was important to 
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assess the baseline values and time as common in all to show any differences 
in weight. 
Z= T/oT 
= (N 1 x Z1 ) + (N2 x Z2) + (N3  x Z3) + (N4 x Z4) + (N5 x Z5) + (N5  x Z5) + (N6 
x Z6) + (N7 x Z7 ) + (NB x Z8)/ [(N1 ) 2 + (N2)2 + (N3)2 + (N4)2 + (N5)2 + (N6)2 + 
(N7)2 + (N8)2] square root 
The meta-analysis involved combining z 's and adding weighted z's 
Formula: 
Z= TI a T= df1Z1 + df2Z2 + ... dfnZn / (df/ + df/ + ... df/) 2 
(Rosenthal, 197 8 ,  p.1 87) 
Or 
Z= T/oT = (N1 x Z1 ) + (N 2  xZ2) . . . / (N /  + N2)2 + Nl... )2 
Therefore sum of z's = (1 60x -2. 33) + (31 7  x -3.00 ) + (17 3  x -3.00)+ (83 x 0 )  + 
(276 X 0 )  + (5 5 5  X -7.5) + (300x0) + (347 X +.50 ) / ((1 60)2 + (317)2 +(173)2 + 
(83) 2 + (276)2 + (555)2 + (300)2 + (347 ) 2] 2 
= -583 1. 8  / (757 5 17 )  square root 
= - 5831. 8 / 870.35 
Sum of z = -6 .700 
p < .0001 
Thus the value of -6 . 700 indicates that the result is highly significant at p < or 
equal to .00 01 and the hypothesis is supported. 
8.5 File drawer calculation is not always necessary, but it clarifies the 
influence of sampling bias (Rosenthal , 1 978). 
X = number of studies needed averaging the null hypothesis, all averaging to 
overturn the finding. 
The formula: 
X = (k / 2. 706) [k (Z k) 2 - 2. 706] 
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(Rosenthal, 1 97 9 ,  p 639) 
z = - 1&.645 
X = 
X = [(- .6 .7 ) sq. 
(8 I 2 .706) [8 ( 
/2 .706] -8 
X = (-.6. 7  x - .6 .7 / 2.700) -8 
= this means that it would take studies averaging 9, z= 0.000 to over turn 
the overall z combined from -6 .7  to - 1 . 64 and therefore no longer s ignificant. 
This calculation of the unseen studies has potential impact on the conclusion 
and is called the file drawer problem (Rosenthal, 1 979) .  
9. Discussion 
The meta-analysis showed significant differences between the conditions to 
there are a few inconsistencies , although the overall result is a strongly 
support the hypothesis that there is weight loss for aripiprazole, compared to a 
few other antipsychotics in this review. Unfortunately , not all the studies 
support that aripiprazole is best for weight loss (Chan et al. ,  2007 ) .  Therefore 
significant one allowing a generalisation to be made of this population sample. 
The pooling of data found that the included studies showed little variation and 
this is a homogenous sample. There was homogeneity of information from the 
studies, which suggest that there are only a few reliability issues. I t  is thought 
that 'many study characteristics may affect study results' but this study does 
not have much variation (Hunter & Schmidt, 2004, p.47 1 ) .  An advantage of 
this review was that the search strategy was flexible. 
Aripiprazole , as an atypical antipsychotic, has a strong positive outcome from 
four of the included studies with significant differences of having weight loss 
with its comparator (Chrzanowski et al. , 2006 ; Kolotkin et al. , 2008; McQuade 
et al. , 2004&; Newcomer et al. ,  2008) whereas the other four studies are such 
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that they showed less strength and consistency, with three of them having 
unclear direction and no significant difference between its groups (Kane et  al. , 
200 2 ;  Potkin et al. , 2003; Vieta et al., 2005) and one study with 'mild weight 
gain' for its groups (Chan et al. , 2007 ,  p.29) .  So these other antipsychotics 
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need to be invest igated separately for interventions in  weight loss and their 
effectiveness. 
The causa l mechanisms were not investigated in this study for weight gain 
and antipsychotics and this would be another area for investigation .  I t  is 
important to point out that previous stud ies have i nvolved participants who 
have normal ly been on medication for thei r  i l l ness over a long period of time, 
before they embarked as participants in these trials, which could ind icate an  
exaggerated o r  imprecise weight gain (Reynolds, 2007) .  The meta-ana lysis 
has provided evidence for arip iprazole to be seen as a promising new drug as 
for weight loss as well as treatment of mental i l l ness; and in relating to weight 
and self-esteem psycholog ical ly, there needs to be understanding of the 
depth of these issues, that include what is a healthy d iet, weight, exercise and 
management issues (Faulkner et al. , 2003). Wei l  at al (2002) found that 
people were conscious of their weight and keen to take measures to reduce 
excess weight in the mental ly i l l  population , even more so than the general 
population.  
Aripiprazole is one of the NGAs, which a re extremely popu lar  i n  the 
' industrial ized ' economies (Kommossa et al. , 2007, p. 1 )  with minimal loss in  
weight that is hoped wil l  mean that arip irazole wil l  a l low treatment to be 
continued for a length of t ime where 'adherence' to the med ication , and with a 
dosage that wi l l  benefit the patient, to encourage maintenance to occur d uring 
their mental i l lness, for long term benefits (Thomas, 2007, p. S1 1 5) .  Although 
the studies that support aripiprazole have claimed that a more positive picture 
for mental i l lness is emerging for side effects such as weight gain ,  there is a 
need to balance the impact of weight gain with the benefits of treatment to 
recovery (Ascher-Svanum et al. , 2005). The wider impact of understand ing 
these issues with the treatment of mental i l lness should a l low for the 
prevention of secondary complications which are associated with weight gain 
(Lean ,  2003). 
There should be monitoring and regular screening while people are on 
medications (Kolotkin et al. , 2008) . Weight gain is a major issue now for a l l  
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those practicing in the health professions and the use of antipsychotics are 
being investigated more closely for their benefits and limitations for weight in 
individuals , since it has been1 found that the side effects vary from individual to 
individual and may not even occur in any depth for a few individuals (Malhi, 
2 003). The problems of weight gain and metabolic disorders have become a 
clinical issue (Thomas, 2007).  
Ethical Issues 
The authors, of the studies used for the review, defined the ethical procedures 
they undertook such as the Declaration of Helsinki and Good Clinical 
Reporting Practice, as well as an ethics committee for approval with 
participants consent in Chrzanowski et al. (2 006)&; Vieta et al. (2 005) pointed 
out that they had ethical approval and participant consent; Potkin et al. (2003) 
similarly received approval from an ethics committee, followed the Good 
Clinical Practice guide, Food and drug Administration regulations, the 
Declaration of Helsinki and consent of participants; and Kolotkin et al. (2&008) 
followed the Declaration of Helsinki ,  received approval by Institutional Review 
Boards and participants gave consent. Whereas for the other four of the 
studies which were abstracts this information was not obtained. The studies 
seem to assess the patients' conditions during their research by their own 
experts which indicate concerns of anonymity, confidentiality and protection 
from harm issues in the knowledge of these participants illness and although 
consent was given (not known for the abstract only studies) the impact of a 
follow up and debrief is crucial in these studies because of the psychological 
issues to respect and reassure participants. There is concern for the cases 
where one patient died (Chrzanowski et al. ,  2 006) , and another where there 
was worsening psychosis (Potkin et al. , 2 003) but in both these studies the 
incidences are clearly stated as un related to study treatments. In  Vieta et al. 
(2 005)  one pat ient had liver damage ' related to study medication' (haloperidol) 
(p.238) which could have been due to dosage. 
A debrief is very important as an ethical issue and a follow-up (Coolican, 
1 990), both of which is not mentioned in nearly all of the studies. There was 
only one follow -up mentioned (Potkin et al. , 2 003). The significance of 
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'psychological harm' from the study cou ld have repercussions or worsen 
mental hea lth if ethics is not dea lt with properly for this group ( ib id . p.254) . 
The eth ica l issues incorporate the ideals such as of anonymity, confidentia l ity, 
a l lowing withdrawal , consent, debriefing, and protection for participants from 
physica l and emotional harm (Coolican ,  1 990). Also on ethical issues the s ide 
effects of weight gain shou ld be informed so there is prevention of 
complications (Lean,  2003) . 
The consequence with taking antipsychotics for the 'blood g lucose' such as 
diabetes (McIntyre et al. , 2005, p. 1 1 8) should be understood with respect that 
people with schizophrenia as wel l  as bipolar d isorder and depression cou ld 
suffer d iabetes regard less of taking these drugs and weight gain ,  because of 
other factors such as the relevance of l ifestyle and genetics (Guthrie, 2002) .  
Aripiprazole has better reviews in metabolic disturbances a longside 
risperidone, quetiapine, and ziprasidone - though there has not been enough 
research on the long-term impact of these drugs to verify this adequately and 
there may be bias (McIntyre et al. , 2005) s ince they are relatively new. 
Simi larly for the association between antipsychotic weight gain and d iabetes 
there has not been enough research to provide conclusive evidence (McI ntyre 
et al. , 2005) ; arid d iabetes and obesity are often related and people with these 
complaints are more l ikely to have depression (Fabricatore & Wadden, 2003). 
The themes identified here require further exploration with participants from 
other popu lations so general isation may occur. There are few RCT's that have 
tested this association between weight gain and antipsychotics (Faulkner et 
al. , 2007). The number of studies for meta-analyses in this review was 
adequate and the study sizes were large (th is study provided a sample size 
that was rel iable N= 2 ,  507) .  A negative point is that the lengths of studies 
were variable - of short duration to medium length (Chrzanowski et al. , 2006; 
Kolotkin et al. , 2008; Vieta et al. , 2005; McQuade et al. , 2004; Newcomer et 
al. , 2008). Kane et al. (2002) and Potkin et al. (2003) stated fixed doses while 
there was variabi l ity in Vieta et al. (2005) which could affect genera l isabi lty for 
results . There were a large proportion of participants leaving studies early 
wh ich cou ld again be a weakness in the design which is a problem for 
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studies). A comparison between the studies was not possible, as weight 
change was not given in all eight studies. The scales of measurement were 
BMI (Kolotkin et al. , 2008) and weight in kilograms and means (Vieta et al. , 
200&5) .  Some of the studies give percentage changes in weight (Ch rzanowski 
generalisability (Vieta et al. ,  2005). These issues made it difficult to 
adequate 
d raw a 
robust conclusion about the meta-analyses. A good point is that there was no 
variability in study methodology since all studies described 
randomisation with blinding procedures except one (Kolotkin et al. , 2008) .  The 
descriptions of the methods were good with inclusion and exclusion criteria 
explained in the included studies (not possible to know from abstracts only 
et al. , 2006). 
Faulkner et al (2003) recommend BMI measurement, although this does not 
consider the 'central fat distribution' or 'intra-abdominal' adipose tissue, which 
is detrimental to health (Lean , 200 3 ,  p. 13). Lean (2003) point out that this 
measurement should be done with a 'waist circumference' measurement, 
which would indicate the depth of this fat distribution (p. 1 4) .  A weakness in 
this review is there were no long- term studies , so an exploration of the 
longer-term benefits of this drug use is d ifficult to ascertain. Another point is 
that inaccuracy ·may happen in the results because patients do not take their 
medication. 
This issue of d isability and mental illness has been classified according to 
cultural perception and society's stigmatization of it; this is s imilar for weight 
gain (Lean , 2003). There have been interrelationships between the issues 
with inequalities in societal attitudes and clinical understanding that does 
seem to be changing with health promotions (Douglas et al. , 2007) . Faulkner 
et al. (2003) propose that clinicians should advocate exercise and diet 
counsell ing alongside antipsychotic therapy, even though changes brought 
about by these modifications may be short term (ibid) ,  and the group may 
arrive with co morbid conditions that exacerbate weight management, that 
make treatment difficult. 
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The issues associated with mental i l lness and weight management appears to 
have not been attended adequately (Connolly & Kelly, 2005) . Connol ly and 
Kel ly (2005) point out that the 'psychological state' is a 'risk factor' and that 
people with sch izophrenia may need support because of the drugs used for 
treatment. They recommend that 'monitoring' with 'exercise and l ifestyle' 
advice should be routinely g iven and switthing med ication to one that has less 
chances of weight increase should be g iven if possible. They suggest that 
l istening to people with sch izophren ia especial ly when they are suffering 
symptoms of the d isease should be vita l  ( ibid) . Whereas for the b ipolar I 
d isorder the issues of weight management require s imi lar judgement and CBT 
has been recommended as wel l  as an appropriate method of treatment 
(N ICE ,  2007) that would equally wel l  apply for adaptation for people with 
schizoph renia (Rector & Beck, 2001 ) with an i ntegrated approach to treatment 
(Schu ltz et al. , 2007) . 
Race d ifferences could be examined for weight gain or loss and this ideology 
should be included in an education program that aims to advice on improving 
hea lth and fitness (Littrel l  et al, 2003) because empathy of cultura l  issues 
would maximise greatest capacity for weight management. All issues need to 
be considered in the context of diet and activity with the s ignificance of age, 
body weight adiposity, and ethn icity as background detai ls that are important 
(Lean , 2003). The sample population cou ld also be considered in view of their 
education and employment as wel l  for extraneous variables) . 
9 . 1  Interventions 
9 . 1 . 1  Weight 
There were min imal d ifferences between the groups of endpoint weight from 
basel ine but they were significant; with mean basel ine weight for arip iprazole 
being 73.6 kg (and 72 . 1  kg for olanzapine) in Chrzanowski et al. (2006, p.266) 
and this was simi lar across the studies . Most participants lost wejght with 
aripiprazole compared to the control group (Chrzanowski et al., 2006; Kolotkin 
et al. , 2008; Newcomer et al. , 2008) . I n  Chan et al. (2007) there was weight 
gain .  
43 
9 . 1 . 2  Discontinuation 
There was discontinuation across the included studies, though the abstracts 
of Kane et al. (2002 )  and Chan et al. (2007) do not specify this loss. 
9 .2 All the eight studies are clear in their allocation of randomisation ;  
community/hospital base and the short term and medium term gain o f  weight, 
but not for age and gender in control of other variables. The inclusion and 
exclusion criteria were compared and differed slightly from each other with 
Kolotkin et al. (2008 ) allowing comcomitant medication, while generally this 
was not allowed (Chrzanowski et al. , 2006; Potkin et al. ,  2003) .  This use of 
concomitant medication is also an issue for worsening disease and needs to 
be known in the studies being conducted (Bushe & Paton, 2005 ). When 
patients take concomitant medications the results may become confounded. 
9 .2. 1  Chan et al. (2007) was a study of asian patients from Taiwan receiving 
aripiprazole as treatment for schizophrenia with risperidone as a control ; with 
findings that were not significant with a little weight gain for both groups .  This 
showed no difference in the result compared to the 'white patients' (p.29 ). 
9 .2 . 2  Chrzanowski et al. (2006) were comparing 'the efficacy and safety of 
aripiprazole with olanzapine' and they had a sample from a predominantly 
'white 96%' background (p.261 ). Unfortunately they also recorded that one 57 
year old woman died due to heart failure which was deemed unrelated to the 
study's medication ;  she had been 'in the olanzapine group' (p.262). Indeed 
past research had identified that olanzapine and clozapine cause more weight 
than some other atypicals (Newcomer , 2004; Reynolds, 2007). Also , in this 
study, there was more weight gain with olanzapine (2 . 54 kg) compared to 
aripiprazole (0.04 kg) (p.263). Aripiprazole also fared better in l ipid profi le 
overall to olanzapine, which is beneficial in adherence, and long term health 
concerns on the medications (p. 265 ) .  
9.2 . 3  Kane et al. (2002) was a short-term study and seen as an abstract only 
with a large number of participants (N= 414 )  conducted in the U .S.A of in 
patients that were investigated for 'EPS, serum prolactin level , and QTc 
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interval - 'as well as' weight gain' (p.763 ) .  Aripiprazole was not implicated in 
high levels of these other  s ide effects or for significant weight differences ( ibid, 
p763) .  
9.2.4 .  Kolotkin et al. (2008) provided re�ults from time taken at 8 weeks as 
time 1. The stages were a three-time stage of 8 ,  1 8  and 26 weeks in this 
study. Overall ,  S. O.C .  had greater weight gain by (27. 9%) 'at least 5% of their 
baseline weight, compared to only 11.7% for aripiprazole (z = -4 .62, p < 
0 .001 )' (p.4) .  This may be explained by controll ing for confounding variables. 
The aripiprazole group 'lost approximately 1.5% of their baseline weight by 
week 8, and maintained that loss throughout the remainder of the study' (p.4). 
This was a significant result but it did not take account for smoking as a 
confounding factor in weight gain/loss or whether they were 'equally 
distributed after randomization' (p .6 ) .  Although the S .O. C. group are also 
atypical antipsychotics their mechanism of working is not as effective to 
counteract the side effects that aripiprazole has advantages over, because it 
is a partial agonist at D2 receptors and at 5HT1A receptors and antagonist 
activity at SHT 2A receptors (Potkin et al. , 2003 ,  p . 690). This was examined by 
Beebe (2003) on treatment of schizophrenia with the atyp ical and typ ical 
medications with the latter in respect of their effectiveness due to their 
blockage of dopamine receptors and encouraging 'dopamine destruction' for 
positive symptoms and the former as preferable in terms of being better for 
the negative symptoms (p.11 6) .  Thus a ripiprazole is called 'a dopamine 
system stabiliser' which is effective in treatment of both positive and negative 
symptoms of schizophrenia (Bandelow & Meier, 2003) . Thus if s ide effects are 
controlled then empowerment to living independently may be achieved with 'a 
good health-related quality of l i fe' (Thomas, 2 007, p. S116). This is a benefit 
to public health issues. 
9. 2. 5  McQuade et al. (2004) the weight gain was defined by a 'greater than  or 
equal to 7% increase in body weight from baseline' (p. 47). In this study 
olanzapine had greater increases in weight compared to aripiprazole. 
Aripiprazole had improved 'lipids profile' and weight that indicates that it has a 
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'potentially lower metabolic and cardiovascular risk in patients treated with 
aripiprazole compared with those treated with to olanzapine' (p. 48) .  
9 . 2 .6 Newcomer et al. (2008) found that when switching to aripiprazole from 
olanzapine there was improved 'weight and lipids' with benefits -· 
psychologically. At the end of the study there was weight loss for aripiprazole 
against olanzapine (-1.8 vs. 1.41 kg; p < .001) (p.1046). 
9.2 .7  Potkin et al (2003) had aripiprazole and risperidone, an atypical 
antipsychotic as a control group, to determine the effectiveness of doses of 
aripiprazole at 20 mg and 30 mg. The weight gain level was set at 'greater 
than or equal to 7% increase from baseline' and found that there was no 
significant difference between the groups (p.688). 
9.2.8 Vieta et al. (2005) was interested in compliance to improve bipolar I 
disorder and compared aripiprazole with haloperidol, a first generation 
antipsychotic. There were more people leaving the study because of side 
effects with haloperidol than aripiprazole (p< 0.001 ). There was no significant 
difference in weight between the two groups. 
The implications of issues such as these mentioned for the 'sampling, 
measurement ,  analyses ,  and findings' validate the study to be repeated 
(Hunter & Schmidt ,  2 004, p.471 ) .  Considering that this drug aripiprazole is 
fairly new on the market then it would be a feasible assumption to make that 
there would be more research as interest and use in this as treatment 
proceeds,  so that the limitations seen will be addressed. These are good 
results with good quality data and a few well-conducted studies comparing 
aripiprazole with other antipsychotics. 
1 0 . Conclusion 
The issue of choices for both the patients and clinicians should be presented 
with the atypical antipsychotics in mental illness with appropriate 
consideration of the patient's needs as well as of ideas of what they 
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understand for improving their lifestyle (Thomas, 2007). The amount of 
dosage of the drugs and time span of treatment is crucial for the best 
treatment (Vieta et al. , 2005). The meta-analysis has shown that the results 
are significant with little variability so that there is a consensus to advocating 
drug therapy. It is apparent that there are risks of weight gain with some 
antipsychotics and atypical antipsych6tics (Schultz et al. , 2007)&. The atypical 
antipsychotic, aripiprazole could be given as a treatment that has a benefit of 
weight loss or minimal weight gain with the hope that long-term weight 
maintenance is successful where it is warranted. 
It is necessary to explore this a rea because the negative impact of not 
managing overweight can lead to obesity and serious illnesses (Newcomer, 
2004) and this is also important to public health practit ioners. Therefore when 
antipsychotic use has produced weight gain this is of significance to health. 
Aripiprazole is just as effective as the past drugs and produces weight loss so 
this is an asset to the individ1Jal's self-esteem and body image . Even though 
the effect of antipsychotics is vital for these illnesses, an overall impact of side 
effects should assess the impact on self image when there is weight gain. It is 
with a tentativeness that the health professionals are awaiting to observe 
whether the good resu lts from the clinical environment will extrapolate to the 
real world for aripiprazole (Naber &Lambert, 2004). This review adds to the 
encouraging evidence that through research a new generation of 
antipsychotics have emerged to bring an optimistic outlook in mental illness 
(Thomas, 2007). 
10 .1 The implications for p ractice 
10.1.1 for mental illness. 
Psychoses and mental i llness a re both debil itating and concerns issues of 
self-management; schizophrenia and bipolar I disorder are conditions that 
require t reatment with antipsychotics that can cause weight gain due to 
environmental ,  genetic or medication (Comer, 2007) . It is well known that 
people with schizophrenia may become overweight Faulkner et al. , 2007). It 
seems that a m inimum weight loss can be achieved but it is not known over 
what time span with the atypical ant ipsychotic aripiprazole (Beebe, 2003). The 
47 
number of studies chosen was important and it was enough to carry out a 
meta-analysis. There were not much variation of interventions and their 
dosage was acceptable, but the time period for studies was all short term and 
medium term. It is better if sufferers of these mental illnesses could turn to 
their clinician and forge a strong rapport for weight management and 
I 
a long 
term treatment plan (Faulkner et al. , 2007 ) . N. I C . E . (2007) and Rector and 
Beck (2001 ) advocate an integrated approach for treatment with combined 
therapy such as CBT. This should be considered for both bipolar disorder 
and schizophrenia. The impact of self image in mental illness is highlighted by 
Weil et al. (2002) since this can lead to suicide if it is not managed adequately 
(Carpenter et al. , 2000)&. 
1 0. 1. 2  for clinicians 
There is 
few to bu ild a strong argument for evidence that treatments do impact on 
not much evidence from research with RCTs because they are so 
weight gain (Faulkner et al. , 2007) . The current data in this review comes from 
single studies and suggests that short-term to medium term modest weight 
loss is possible . The priority should be to ameliorate the severity of the 
condition but weight gain or metabolic disturbance should also be an issue 
because of the various serious compl ications associated with this. 
Psychoeducation of patients, family, and caregivers should be about the 
metabolic risks and lifestyle advice regarding diet and physical activity 
(Merinder, 2000) and on any 'adjunctive psychosocial treatments on 
antipsychotic effectiveness' ( Bagnall et al. 2003 , p. 8 ) . The significance of 
screening and monitoring at the beg inning of antipsychotic treatment should 
be administered to reduce the risks of the metabolic disturbances (Smith et 
al. , 2008 )&. Drugs such as Orlistat for this population is an 
treatment (Connolly & Kelly, 2005) which is suitable for patients who 
'anti-obesity' 
cannot 
adapt to 'lifestyle interventions alone' (Faulkner et al. , 2007 , p. 38 ) .  
10. 2 For managers and policy makers 
An awareness of the health issues related to weight gain is important ; and the 
prognosis of this population should be a concern because if the situation of 
obesity is ignored , it will incur financial liab ilities (Harvey et al. , 2001&) .  
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1 0.3  Impl ications for research 
1 0 .3 . 1 General 
Defin itions are important and the standardisation of reporting data for meta­
analysis should be also consistent. This was seen in the included studies. The 
clarity of methods of randomisation g ives confidence i n  the stud ies that 
selection bias had been minimised and controlled , and that the double 
bl inding has enabled better conduction of performance and detection bias 
(Jun i  et al. , 2001 ) .  The reporting of outcomes with means and standard 
deviations wou ld provide usable data and facil itated synthesis of find ings. I t  is 
preferred to have the exact numbers and standard deviations when a graph is 
depicted , as this was unclear in  Potkin et al. (2003) (Gil l ies et al. , 2005, p . 14) .  
1 0 .3 .2 Specific 
I n  treatment with antipsychotic medications further randomized controlled 
studies with longer treatment duration are needed to explore the effectiveness 
and safety of both atypical antipsychotics and antipsychotics of the first 
generation for preventing weight gain and or bringing about weight loss i n  
mental i l lness (Bagnal l et al. , 2003) . Studies should state in itial and endpoint 
values i ncluding means d ifference and b inary outcomes that are descriptions 
such as the number of patients losing '> or = 7%' in itial body weight' for 
interpretation information and clarity (McQuade et al. , 2004, p.47) . The 
methods section for the sample population and interventions should be 
precisely described and the results should encompass the participants who 
had left early to be followed -up .  
These eight stud ies represented large studies that seem to be well designed 
and log ical ly reported for the ful l  accessed articles. These stud ies main ly 
used weight in ki log rams and means or BMI as the outcome measure. Other 
measures such as waist-to-h ip ratio and waist circumference should also be 
i ncluded because BMI does not recogn ise fat d istribution (Lean ,  2003). The 
distribution of weight gain needs to be examined (Littrel l  et al. , 2003) and 
there needs to be further research for the in itial period of antipsychotic 
49 
treatment when there appears to be the most increases in weight (Faulkner et 
al. , 2007). 
The quality of evidence was good on the effectiveness of treatment with 
aripiprazole for weight loss on short to medium term duration, but 
generalisations are not acceptable to the rest of the mentally ill population as 
definitions vary and they tend to be based on limited evidence and should be 
treated with caution. Further research is needed. There are financial 
implications with introducing the medications, along with the methodology, 
and 'new innovative approaches to achieve long term weigh loss are 
necessary' (Addington et al., 2003, p.275). 
10.4 Recommendations 
RCTs comparing other atypical antipsychotics with one another would be 
beneficial (Bagnall et al. 2003). It is important to specify research comparisons 
and interventions for either antipsychotic versus antipsychotic or of atypical 
antipsychotic versus atypical antipsychotic clearly so that it is known what 
their working mechanisms for effective treatment are. This is done, for 
instance, to investigate if the NGAs work similarly or differently to one another 
(Kommossa et al., 2007), to offer better patient choice (Gardner et al. , 2005). 
Research into combined therapies compared with the atypicals is also a good 
idea (Bagnall et al. , 2003). 
Further research using RCTs could be done on the young and the elderly 
(Bagnall et al. 2003) and first episode and long term cases as well to observe 
for other side effects such as for 'prolactin' and 'sexual' problems which had 
been 'poorly reported' (Bagnall et al. 2003, p. 7). The impact of gender and 
ethnicity should also be determined in relation to antipsychotic drugs (ibid). 
This review has provided evidence that aripiprazole is beneficial in treatment 
with weight loss and that aripiprazole may prevent relapse (McQuade et al., 
2004). 
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11. Dissemination 
The review will improve awareness for the general public, develop and 
improve the accessibility of services for sufferers and educate for better 
lifestyle for family as well; and to keep those in the health professions up to 
date. This study has objectives to disseminate through the media, community 
involvement, and influence health care professionals (WHO, 1991, p.154}. 
There is a need to inform various professional organizations of the academic 
production of this review because influence is needed to fund and provide 
resources for further research. The issues of this review could be particularly 
well suited to dissemination at conferences with 'posters sessions' (Polit & 
Hungler, 1993, p.51), which could be supported by academic or professional 
organizations with a presentation in the form of verbal or 'visual displays' (ibid, 
p. 51). 
12. Limitation and potential conflict of interest 
There is none known. 
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1 3. Reflection 
I feel that my attitude to learning has expanded , by learning about these 
issues. I have worked very hard to grapple with the terminology and realise 
that there are a number of concepts that are a part of this area, but a few 
major ideas are enough at this stage for me to deal with , so what I have 
presented in  this review of a complex issue is one that is hopefu lly interesting 
and succinct. 
Th is dissertation has provided the learning experience for me where my 
outlook of meta-analysis has developed with an appreciation of the methodical 
approach that it provides. The idea that it is a methodological approach to 
searching information has had various issues for me in  producing this work -
some personal and some academic, but the chal lenge has been rewarding 
(Greenhalgh, 2002). Basically, since I am very chaotic in my organization 
mentally of approaching work, and it is not unusual for me to dip in and out of 
various sections as and when ideas occur - I set strict targets and goals so 
that this ideology would not pass me by. The defin itions needed to be 
understood and I knew that I should aim to review between 8-20 studies with 
starting the l iterature review. Structure became very crucial to achievement 
and the methodological issues were pertinently at the fore so the inclusion 
and exclusion issues were considered for the review. 
There was a lot of collating facts together and ideas on the topic, and printing 
off but I knew that noth ing should be thrown away. This was time-consuming 
and an on going process to the end. Next, came the reading and assimilating 
of information and to start the search for the meta-analysis. I thought about 
the inclusion and exclusion criteria first. All this had to be an objective 
approach with preparation being the key; and adherence to targets. I had 
produced a Gantt chart in  my proposal with timelines and this time span I 
found was limited , considering the vast quantity of work required. There was 
more work involved than met the eye initially because it was al l  very detailed. I 
soon realised that I was missing the Gantt chart deadlines first, then my own 
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I 
deadlines, and by the stage of the write up I was far behind because of the 
confusion with the information and l iterature. 
Focussing was very important as there was a huge amount of information all 
very much similar. The subject proved to be more complex than appeared at 
first sight and a direction was important. Thus meeting up with Andy and 
Sandra helped clarify the areas of concern such as the structuring of the 
systematic review and basic knowledge of what a systematic review is and a 
meta-analysis. Every meeting was beneficial in building up a picture for the 
review and its development. This allowed a positive aim for me to work at the 
sections because I could take in work for meta-analysis and ask questions. 
The Professional Academic Development team also helped me to understand 
the synthesis of work and in improving my planning skills. Defin itions are very 
important and finding out about g lobal measures as a concern with mental 
health was a definition amongst many that I came across. 
felt that people suffering mental i l lness need more support because 
information is not as accessible. This was an assumption that I had from the 
beginning and that awareness of concepts such as d iscrimination is an 
important issue to raise with the publ ic, alongside the fact that dietary issues 
should be taken more seriously in mental health . The reading has provided an 
in depth account of relevant history and I was surprised that there were so 
many d rugs that produced weight gain. 
If th is had been a study that was going to be published then time permitting , I 
would have tried to access the full journal articles that were only obtai ned in 
this review as abstracts (four of them). This would have been done by 
requesting authors of relevant studies. I wou ld also contact them to find out 
about those leaving the study early since a follow -up or debrief was not 
particularly well proffered; I would like to examine this further. I had to balance 
my introduction and this took much longer than I expected to finish, in fact 
right to the end ! Schizophrenia is a psychosis whereas bipolar I d isorder is 
not, so I needed to balance my perspective of mental i l lness and psychoses 
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when writing my dissertation, without getting my personal interests involved in 
one more than the other. 
The hypothesis was formed when ideas were still growing ; and there were 
changes being made to the criteria for including studies when it seemed 
apparent that time was a limitation - so antipsychotics as a comparison was 
decided on for the atyp ical antipsychotic, aripiprazole - and haloperidol was 
chosen, which was a conventional antipsychotic. This was instead of 
comparing atypical antipsychotics with atypical antipsychotics. The areas that 
I could have covered with the participants in the research studies I reviewed 
may have been gender, socioeconomic status, race and culture if there were 
full articles available. 
It is important to appreciate that this piece of research should advance human 
understanding of the topic because the issues in this have been very profound 
since it revolves around our health and affects are mortality and susceptibil ity 
to i l lness. Since there are few randomised studies in this  area this may 
provide a contribution to encourage more research and d issemination would 
further create awareness and support, bearing in mind that it is the economic 
and political climates that dictate the funding possible for this population and 
others in generating the changes for improvements (Darnton-hil l et al., 2004). 
The reflection is a part of the experience of modern day understanding for 
working and al lows us to consider what one is capable of with a view to further 
development. I t  enables effective reasoning and acceptance of l imitations in 
working. I found that I wanted to pore through all the l iterature that I had 
printed out only to realise that I do not have the time to utilise them al l .  Thus I 
needed to feel confident in what I have produced to the best of my knowledge 
and believe that I am part of a learning process at this level where there are 
going to be limitations. The d issertation has provided an insight into my 
learning where I feel that I have been a part of generating a provocative 
contribution to an issue that has been revolutionary. 
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Appendix 1 .  Aripiprazole. 
Brand : 
Abi l ity® (Dynamic Medical, 2008, p. 1 )  
Chemical Name: 
3 ,  4-dihyd ro-7-[4-[4-(2, 3-dichlorophenyl)-1 -piperazinyl] butoxy]-2(1 H)­
Quinolinone (Dynamic Medical , 2008 , p. 1 )  
Treatment: 
Schizophrenia (Miyamoto et a l . ,  2005) 
Bipolar I Disorder with acute manic and mixed episodes (Vieta et al . , 2005; 
Keck et a l . ,  2003) 
Genera l  adverse Effects: 
Headache, insomnia, and anxiety (Beebe, 2003). 
Dosage: 
The preferred doses for aripiprazole are 1 0-30 mg/day (Bandelow & Meier, 
2003, p. 14) .  
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Appendix 2. Characteristics of included studies 
Study Kolotki n  et al. (2008) 
Methods Allocation: random ized 
Bl indness: not stated 
Duration: 26 weeks 
Design :  Arip iprazole (ARI) vs. standard of care (SOC , 
consisting of olanzapine, quetiapine, and 
risperidone). 
Participants Diagnosis: Schizophrenia (DSM-1V-TR criteria) 
N= 555 
Age: mean 38.5 years (SD 1 0. 9) 
Sex: 59 .7 % M 
History: Signed informed consent. 
Setting:  Natura l istic (community treated or hospital-based 
outpatient centre) , m u lticentre (98) , open label 
study. 1 2  European countries 
I nterventions 1 .  Aripiprazole, dose: 1 0-30mg/day or 
2. Standard of Care 
- Olanzapine ,  dose: 5-20 mg/day, or accord ing to the 
approved local med ication label ,  or 
- Quetiapine, dose: 1 00-BOOmg/day, or according to the 
approved local medication label , or 
- Risperidone, dose: 2-8 mg/day, or accord ing to the 
approved loca l med ication label 
· Outcomes · Weight: Mean  basel ine body mass i ndex of 27 .2 (SD 5 . 1 ) .  ARI · 
participants lost an average of 1 .7 % of basel ine weight in 
comparison to a gain of 2 . 1  % by SOC participants (p< 0 .000 1 ) 
at 26 weeks (p. 1 )  
70 
Study 
Methods \ 
Participants 
Interventions 
Outcomes 
Study 
Potkin et al. (2003) 
Allocation: randomised 
Blindness: double 
Duration: 4 week 
Design :  Aripirazole , and risperidone vs p lacebo. 
Diagnosis: Schizophrenia or schizoaffective diso rders 
(DSM&-IV) 
N=&404 
Age : 1 8-65 years 
Sex: both 
History: Written informed consent. 
Setting :  Multicentre (40 Medical centres). U. S. 
Hospitalized 
1. Aripiprazole , dose: 20 mg/day or 
2. Aripiprazole 30 mg/day. N= 1 01 or 
3 . Placebo N= 103 ,  o r  
4. Risperidone 6mg/day 
The percentage of patients with significant weight gain was 
evaluated by the Cochran-Mantel- Haenszel test (p .4) ; both 
groups showed a 'low incidence of cl inically significant weight 
gain ' (p.1 ) 
Vieta et al. (2005) 
Methods Allocation :  randomised 
Blindness: double 
Duration : 1 2  weeks 
Design: Aripiprazole versus haloperidol 
71 
Participants D iagnosis :  
Age:  
Sex: 
H istory: 
Setting : 
Bipolar I d isorder with acute or m ixed episode 
(DSM-IV) . 
N= 347 
1 8-65 years 
both 
Written informed consent or lega lly acceptable 
representative . 
Mu lticentre (76 internationa l ly) .  I npatient or 
outpatient treatment. 
I nterventions 1 .  Arip i razole 1 5  mg/day N=1 75,  or 
2 .  Haloperido l  1 0mg/day N=1 r72 . 
Outcomes 'min imal  mean changes in body weight' with both g roups (p. 241 ) 
Study 
Methods 
Participants 
Al location : 
Bl indness: 
Duration :  
Design :  
Diagnosis :  
Age :  
Sex: 
H istory: 
Setting: 
Kane et al. (2002) 
randomised 
double 
4 weeks 
Arip iprazole versus haloperidol versus placebo 
sch izoph renia or sch izoaffective d isorder (DSM-IV) . 
N= 4 1 4  
not stated in abstract 
not stated in abstract 
not stated in abstract 
36 U .S .  centres 
I nterventions 1 .  Aprip iprazole 1 5  mg/day, 30 mg/day 
2. Haloperidol 1 0 mg/day 
3. p lacebo 
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Outcomes 'm inimal mean changes in body weight' with both groups (p. 24 1 )  
Study 
! Methods Allocation: 
Blindness: 
Duration: 
Design: 
Participants Diagnosis: 
Age: 
Sex: 
H istory: 
Setting : 
Chan et al. (2007) 
randomised 
double 
4 weeks 
Aripiprazole versus risperidone 
schizophrenia or sch izoaffective disorder (DSM-IV). 
N= 83 
not stated in abstract 
not stated in abstract 
not stated in abstract 
5 med ical centres , Taiwan 
Interventions 1 .  Apripiprazole 1 5  mg/day, n=49 
2 .  Risperidone 6mg/day, n=34 
'Both goups showed rn i ld weight gain' (p. 29) . Outcomes 
Study 
Methods Allocation: 
Blindness: 
Duration: 
Des ign: 
Participants Diagnosis: 
Age: 
McQuade et al. (2004) 
randomised 
double 
26 weeks 
Aripiprazole versus olanzapine 
schizoph renia (DSM-IV) .  
N= 31&7 
not stated in abstract 
73 
J Sex: not stated in abstract 
, History: not stated i n  abstract 
Sett ing: Multicentre, hospita l isation 
I nterventions a rip iprazole n= 1 56 ,  
olanzapine n= 16 1  
dosage not stated in abstract 
Outcomes 'By week 26, 37% of olanzapine-treated patients had 
experienced sign ificant weight gain compared with 1 4% of 
arip iprazole-treated patients (p < . 00 1 ) ' (p . 47). 
Study Newcomer et al. (2008) 
Methods Allocation : randomised 
Bl indness: doub le 
Duration : 1 6  weeks 
Design :  Aripiprazole versus o lanzapine 
Participants Diagnosis : schizophren ia or schizoaffective d isorder (DSM -
IV-TR) 
N= 1 73 
Age : not stated in  abstract 
Sex: not stated in abstract 
H istory: not stated in abstract 
Setting : Mu lticentre 
I nterventions Arip iprazole n= 88 or 
o lanzapine n= 85 
dosage not stated i n  abstract . 
Outcomes 'At week 1 6 , weight decreased significantly with a rip iprazole 
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Study 
Methods 
Participants 
I nterventions 
Outcomes 
vesus olanzapine (-1 .8 vs. + 1 .4 1 kg ; p < . 00 1 )' (Newcomer et al. 
2008 , p . 1 )  'Significantly more subjects receiving arip iprazole had 
cl i n ical ly relevant (> o r  = 7%) weight loss versus olanzap ine 
( 1 1 . 1 % vs. 2 .6% ; p = .038) ,  and a lower percentage of subjects 
receiving arip iprazole had cl in ical ly relevant weight ga in (2 .5% 
vs. 9 . 1 % ; p= .082)' ( ib id , p . 1 )) .  
Chrzanowski et  al. (2006) 
Al location: randomised 
B l i nd ness : double 
Duration : 52 weeks 
Design :  Arip iprazole versus olanzapine 
Diagnosis: schizoph renia 
N=c2 1 4  
Age:  not stated i n  abstract 
Sex: 54% M; 46% F 
History: informed written consent 
Setting: Mu lticentre , open labe l .  
Arip iprazole dose 1 5-30mg/day, n= 1 04, or 
olanzapine dose 1 0-20 mg/day, n= 1 1 0 
'At study end , mean weight ga in with olanzapine was 2 . 54 vs. 
0 .04 kg with ar ip iprazole (p<0 .00 1 ; LOCF)' (p .  263) . 
I 
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Append ix 3 .  Characterist ics of excluded studies 
Study 
Methods 
Participants 
I nterventions 
Outcomes 
Kerwin et al. (2007) 
Al location :  random ised 
B l i nd ness: 
Duration :  2 6  weeks 
Design :  Arip iprazole (ARI)  vs . standard of care (SOC , 
consist ing of olanzapine, quetiap ine ,  and 
r isperidone) . 
Diagnosis :  Sch izoph renia (DSM-1 V-TR) 
N= 
Age :  1 8-65 years 
Sex: M; F 
H istory: Written informed consent obta ined .  
Sett ing : Natura l ist ic (commun ity practice o r  hospita l-based 
outpatient (98) mu lticentre ,  open- labe l .  1 2 
European countries) 
1 .  Arip iprazole ,  N = 268 , dose : 1 0-30mg/day or 
2 .Standard of Care - Olanzapine ,  dose : 5-20 mg/day, or 
accord ing to the approved loca l med ication labe l ,  or 
Quet iap ine ,  dose : 1 00-800mg/day, or 
accord i ng to the approved loca l  med icat ion labe l ,  or 
Risperidone, dose : 2- 1 6mg/day, or 
accord ing to the approved loca l  med ication labe l .  
Weight :  SOC -treated group had cl i n ical ly s ign ificant weight 
ga in (2 1 .2 % vs . 7 . 3% for ar ip iprazole) 
Reason for exclusion rep l ica data of Kolotkin et al. (2008) 
76 
Study 
Methods 
McElroy et al. (2007) 
Al location :  Prospective , nonrandomized 
Bl indness: None 
Duration : 8 weeks 
Design :  Arip iprazole as monotherapy 
Participants: 3 1 
Participants Diagnosis: Bipolar depression I N= 1 7 , bipolar I I  N= 1 3 , bipolar 
NOS N= 1 {DSM-IV) 
N= 
Age:  1 8  and over 
Sex: both 
H istory: Written informed consent. 
Setting :  Open -label 3 sites, out-patient 
I nterventions 1 .  Arip iprazole , dose: 1 5mg/day or  5- 1 0  mg/day and increased to 
30mg/day. 
N=1 3 (42%) Arip iprazole as monotherapy 
N= 1 8  (58%) arip iprazole adjunctively. 
Outcomes T- tests were used to assess changes in weight. 
Weight: Ins ign ificant weight ga in statistica l ly (0.8 +/-2 .5 kg) (p. ) 
Reason for 
exclus ion 
The design is the reason for exclusion, s ince 
a rip iprazole being investigated as monotherapy or 
therapy 
it is  on ly 
adjunctive 
Study 
Methods 
Sachs et al. (2006) 
Allocation : randomized 
Bl indness: double 
Duration :  3 weeks 
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Participants 
I nterventions 
Outcomes 
Reason for 
exclus ion 
Study 
Methods 
Participants 
Design :  Arip iprazole vs  placebo. P lacebo control led tria l 
Diagnosis :  B ipo lar I d isorder experiencing an  acute man ic or 
m ixed 
N=272 
Age: 1 8  years and over 
Sex: Not stated 
H istory: written consent. 
Setting :  Hospita l ized . U .S .  29 centres 
1 .  Arip iprazole, dose: 30mg/day (cou ld be reduced to 1 5mg/day) 
N= 1 37 ,  or 
2. P lacebo N=1 35 
'Arip iprazole treatment resu lted in  no sign ificant d ifference from 
placebo i n  change in  mean body weight' (p .  ) 
The design is the reason for exclus ion , s ince a rip iprazole is be ing 
investigated with a p lacebo and a p lacebo in the design is an 
exclusion criteria 
Keck Jr . et al. (2003) 
Al location :  random ized 
B l i ndness: double 
Duration : 3 weeks 
Design :  Placebo-control led tria l  of arip iprazole 
Diagnosis :  B ipolar with acute manic or mixed episode (DSM-
IV) 
N=262 
Age :  18  years and over 
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I Sex: both 
History: written informed consent. 
Setting :  Multicentre (38) .  U .S. Hospita l ized at least 2 
weeks. 
I nterventions 1 .  Arip i razole, dose: 30 mg/day (reduced to 1 5mg/day for 
tolerabi l ity). N= 1 30 ,  or 
Placebo N=1 32. 
Outcomes 'Both treatment g roups experienced a smal l decrease i n  body 
weight du ring the study, and there was no sign ificant d ifference 
between groups in  the incidence of cl in ically s ign ificant weight 
ga in '  (ref. ) .  
Reason for The des ign is the reason for exclusion s ince i t  is a p lacebo-
exclusion control led tria l .  
Study Karunakaran et al. (2006) 
Methods Allocation :  randomized 1 
Bl indness: 
Duration : 
Design :  case notes 
Participants Diagnosis : schizophrenia 
N=26 
Age :  mean 39 .04 (+ or - 9 .95) years 
Sex: 1 9 M ; 1 7 F 
History: 
Setting :  
I nterventions 
I 
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Outcomes Mean level: weight 95.2 kg 1 8  out of 24 (75%) lost a mean 
weight of 5.05kg 
Reason for The design is the reason for exclusion because this is a review of 
exclusion case notes. 
Appendix 4. Adding weighted z's. 
This was done firstly as a meta-analysis value for the following studies by 
Keck et al. (2003), Sachs et al. (2006) , McElroy et al. (2007) , Kolotkin et al. 
(2008), Karunakarun et al . ,  (2006) . 
Adding weighted z's 
Z= T/oT = (N1 x Z1)+(N2 xZ2)/(N1)
2 - + (N2)
2 +(N3)2 · 
= (278x-1 .65)+(31 x1 .6)+(1 37x0)+(20x-2 .58)/ (278)2 +(3 1 )2 + (1 37)2 
+( 1 30)2 +(1 00)2 +( 1 74)2 +(20)2 
= -460.7/ ( 1  54590) sq. root. 
= -460.7/393.2 
p= . 50 
z= -1 . 1 7  (p=. 1 2) 
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Appendix 5. The Fisher's f .. test. 
The illustration below shows the p -value as alpha for a one-tailed Fisher F­
test (Soper, 2008, p. 1 )  
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Appendix 6. Raw data (see floppy disc) 
1 .  Chan et al. (2007) 
Aripiprazole vs. Risperidone 
Tota l N= 83 
At 4 weeks no sign ificant d ifference z=0 . 00 
2 .  Ch rzanowski et al. (2006) 
Arip iprazole vs. olanzapine 
'olanzapine was associated with s ign ificantly greater weight gain than 
a rip iprazole at a l l  time points' (p . 259 ) 
Time points were at weeks 8/1 6/28/52 
Week 52 (last observation carried forward - LOCF] : + 2 .54 vs. + 0 . 04 kg ; p< 
0 .001  
=At week 28  n 1  = 7 1 , n2 89, total N= 1 60 .  
=p< . 0 1  zr -2. 33 
N= 1 56 ,  1 6 1  
Weight for a rip iprazole 73 .9 kg and ( 1 r.7)  S .E .  (standard error) . Weight  for 
olanzap ine 72. 1 kg and ( 1 . 78) S . E. (p .  262) 
3 .  Kane et al. (2002) 
Aripiprazole vs. haloperidol (aga inst p lacebo) 
atr4 weeks 
N = 4 1 4/3 for each group 
n= 1 38 for a rip iprazole, n= 1 38 for haloperidol and n = 1 38 for placebo .  
Assume N = 276 for a rip iprazole and haloperido l  tota l .  
p < or = . 05  z = 0 .00 
No sign ificant difference .  
4 .  Kolotkin  et al. ( 2008) 
Arip iprazole vs. S .O .C .  
The meta- analysis for a rip iprazole vs . standard of care (S.O .C .) to  see if 
arip iprazole is lower at Time 2 (T2) than S .O .C .  
N = 555 total 
Weight loss for a ripiprazole participants on  average of 1 .  7 % of baseline i n  
comparison to a ga in  of  2 . 1 % by S .O .C .  participants (p< 0 .000 1 ) a t  26 weeks . 
(p. 1 )  
=Fisher's  exact and chi square used for weight gain/loss zr -4.6 p<0 .00 1 at 8 
weeks arip iprazole vs S .O .C .  
BM I i s  27 .2  for a ripiprazole (n=278) } 
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and mean , SD is 5.2. } significance 
=BMI is 27.3 for S .O.C.  (n=266) } t (536) -0. 1 3, 
and SD is 5 . 1  } p=0.893 
p<.  000000 
z=-7 .5 
t=7 .5  
Intervention at week 8 n=222 for aripiprazole at t ime 1 .  
=n 2 1 9  for S.O.C. 
=F (3,  1 146) 25 .98 p<0.0001 
The result taken from research by Kerwin et al. (2007) , which was done first, 
is -1 .45 
p< .05 significant reduction 
n=278 
= z=p . 05 - 1 .65 
5. McQuade et al. (2004) 
Aripiprazole vs. olanzapine 
At week 26 37% of olanzapine had significant weight gain vs. 1 4% of 
aripiprazole. 
p< .001 z= -3.00 
Total N= 3 1 7  
At week 26, 'mean weight loss of 1 .37 kg(3.04 lb) with aripiprazole compared 
with a mean increase of 4.23 kg (9.40 lb) with olanzapine among patients who 
remained on therapy' (p. 47) 
6.  Newcomer et al. (2008) 
Aripiprazole vs. olanzapine 
N= 1 73 
At 1 6  weeks weight decreased significantly for aripiprazole versus olanzapine 
(-1 . 8kg vs. + 1 .4 1 kg; p< .00 1 )  
=n=88 for aripiprazole, n 85  for olanzapine. 
p< . 001  z= -3.00 
'Significantly more subjects receiving aripiprazole had clinically relevant (> or 
= 7%) weight loss vs. olanzapine (1 1 . 1  % vs. 2 .60%; p= .038 and a lower 
percentage of subjects receiving aripiprazole had clinically relevant weight 
gain (2.5% vs. 9 . 1 %; p= .082) (p. 1 046). 
7. Potkin et al. (2003) 
Aripiprazole vs. risperidone + p lacebo 
N= 404/3 
n= 1 0 1  for aripiprazole, n= 1 00 for risperidone, n= 99 for placebo. 
N= 300 z= 0.00 z=0 
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Non sign ificant minimum increase across 1 .2 kg , .8kg , 1 .5kg but significant 
difference to placebo ( p. 688). 
t - tests or chi square for placebo vs. a ripiprazole 
No significant d ifference. 
8. Vieta et al. (2005) 
Aripiprazole vs . haloperidol 
N= 1 74 at week 1 2  (L.O.C.F . )  
There was no significant difference for a ripiprazole (0.27 kg) in weight change. 
N=347 z=+0.50 
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6. 
Answer the following question by ringing/deleting yes or no as appropriate: 
1 .  Does the study involve vulnerable participants or those unable to give 
informed consent (e.g. children, people with �ng disabilities, your own 
students)? Yes �
2. Will the study require permission of a gatekeeper for access to participants 
(e.g. schools, self-help groups, residential ho[ReS)? 
Yes /No ,; 
3. Will it be necessary for participants to be in\ratved without consent (e.g. covert 
observation in non-public places)? -� 
Yes /Nol 
4. Will the study involve sensitive topics (e.g .�� activity, substance abuse)? 
Yes 
5. Will blood or tissue samples be taken from · ·pants?
s. 
Will the research involve intrusive intervent, �e.g. drugs, hypnosis, 
physical exercise)? Yes o , 
Yes No 
7. Will financial or other inducements be offere participants (except i
reasonable expenses)? Yes o 
8. Will the research investigate any aspect of i activity?
Yes No 
9. Wil l  participants be stressed beyond what is al for them? 
Yes �N<!) 
/ 
Yes 
Signature of Applic�f/1. . .  4---
Signature of Director of Studies . . . . . . . . . . . . . . . . . . . . . . Date . . . . . . . . . . . . . . . . . . .  . 
SECTION B Consideration by Research Institute 
B(i)
If the answers to Questions 1 to 8 are no and the irector of the Research 
Institute considers that: 
There are no significant ethical issues 
Signature of Director of Research lnstitut Date. _i_l� . .f
10 (.QJ/. . . . .  . .  
10 .  Will the study involve participants from the �e.g. patients or staff)? e, 
Date . .  Xl/ .Pelo.':?. 
This form should then be filed with the RS1 form 
B(ii)
If the answer to any of the questions 1 to 8 is yes o r  if there are other significant 
ethical issues then further ethical consideration is required. This further ethical 
consideration will involve scrutiny by local ethics research committees as 
appropriate. Once this has been undertaken this form, together with the research 
proposal and the recommendations from the further ethical consideration should 
be submitted to the University Research Ethics Committee for approval. 
Please note if the answer to Question 6 is yes then the proposal should be 
submitted through NHS procedures to the appropriate COREC. The University 
Research Ethics Committee should be informed of the outcome.) 
There are significant ethical issues see recommendation attached 
Director of Research Institute . . . . . . . . . . . . . . . . . .  . . .  . Date . . . . . .  . . . . . .  . 
This fonn together with the recommendation and a copy of the research proposal 
should then be submitted to the University Research Ethics Committee 
SECTION C Consideration by University Research Ethics Committee 
The University Research Ethics Committee has 
Approved / not approved 
This application for ethical approval 
Chair University Research Ethics Committee . . . . . . . . . . . . . . . . . . . . . . . .  Date . . . . . .  . . . . . .  . 
If successful a copy of this approval should be included with the RS1 Form in the 
student's file. If the application is unsuccessful formal feedback will be provided. 
